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ABSTRACT 
Cardiovascular diseases remain a leading cause of morbidity and mortality 
in the world, despite advances in drug and therapeutic developments. The complex 
nature of cardiac diseases such as myocardial infarction and heart failure require 
innovative approaches to elucidate disease mechanisms, identify molecular 
targets and develop novel therapies. The advent of human pluripotent stem cell 
(hPSC) technologies allowed for robust and reliable generations of contracting 
human cardiomyocytes (CMs) in vitro. hPSC-CMs hold great promise for a broad 
range of research and clinical applications including studying myocardial 
physiology, modeling cardiac diseases, and transplanting healthy cells to repair 
the damaged heart. However, one major limitation of hPSC-CMs differentiated in 
vitro is that they are relatively immature and resemble embryonic CMs. These cells 
lack well defined cellular edges and mature sarcomeres, which makes it difficult to 
quantitatively assess contractile functions using traditional edge detection 
technologies. In addition, hPSC-CMs cultured in traditional glucose rich media lack 
metabolic and functional maturity, utilizing mainly glycolysis for energy production, 
similar to the embryonic heart. To address these limitations, we first devised a 
 
 viii
novel technology to simultaneously quantify hPSC-CMs’ contractile kinetics, force 
generation and electrical activities at the single cell resolution. This methodology 
allowed us to examine the impact of energy substrates and metabolic pathway 
utilization on CM physiology and function. We identified that Hypoxia Inducible 
Factor 1 alpha (HIF1α) and its transcriptional target Lactate Dehydrogenase A 
(LDHA) are aberrantly upregulated in hPSC-CMs cultured in traditional glucose 
rich media. By using small molecules and siRNA, we demonstrated that inhibition 
of HIF1α/LDHA shifts hPSC-CMs’ metabolism from glycolysis to oxidative 
phosphorylation, which resulted in improved CM structural and functional 
maturation. Furthermore, we investigated the energy substrate dependency of 
hPSC-CMs in response to in vitro hypoxic and ischemia-reperfusion injuries. We 
observed that hPSC-CMs cultured in glucose rich media lack physiological 
responses to hypoxic insults. On the other hand, in vitro coverslip ischemia-
reperfusion resulted in CM death and apoptosis, independent of glucose cultures. 
These findings highlighted the importance of bioenergetics in modeling cardiac 
diseases in vitro and provided us with the basis for a potential drug screening 
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CHAPTER ONE: INTRODUCTION 
 Acute myocardial infarction (MI) is a major cause of cardiac dysfunction and 
heart failure1,2. MI occurs when the blood supply to the heart has been significantly 
diminished to maintain physiological cardiac function and homeostasis2,3. Despite 
recent advancements in therapies, acute MI still leads morbidity and mortality rates 
in the world3,4. Myocardial ischemia, when lasted for an extended period, can result 
in irreversible damage and death to the myocardial cells. Subsequently, heart 
failure can occur when an ischemic insult result in significant loss of myocardium 
leading to an insufficient cardiac output for maintaining organ perfusions5,6. The 
most effective strategy for reducing the myocardial infarct and limit damage to the 
cardiomyocytes (CMs) is early myocardial reperfusion3,7. Reperfusing an infarcted 
heart can restore blood flow required for normal cardiac functions. However, 
reperfusion itself has been found to induce further injuries on myocardial cells3,7. 
This phenomenon has been termed myocardial reperfusion injury. 
 The molecular and cellular mechanism in which myocardial ischemia 
reperfusion (IR) injury results in further cardiac injuries and cell death has been 
widely debated. Multiple mediators have been suggested to be responsible for 
lethal reperfusion injuries including oxidative stress, Ca2+ overload, pH and 
metabolic fluctuations and inflammation3,7. Many clinical studies have attempted 
to reduce reperfusion injuries in patients with acute MI. The therapeutic strategies 
include antioxidants8-10, reducing intracellular Ca2+ overload11-13, anti-inflammatory 




Few studies had moderate short-term successes whereas most of the trials 
showed no effect on infarct size, cardiac function or mortality3,7. These failures in 
the IR clinical trials are partially due to a lack of understanding on the specific 
physiological and molecular mechanisms responsible for CM damage and death. 
Elucidating the critical mechanism of cellular apoptosis and perform appropriate, 
timely therapeutic interventions are keys to improve patient outcomes and mortality 
rates.  
 As a result, developing in vitro models of myocardial ischemia has been 
important for the elucidation of the mechanisms of ischemic injury and the 
development of novel cardioprotective strategies. Various cell types have been 
explored for in vitro models of IR injury including chicken embryonic CMs, murine 
neonatal CMs, murine adult CMs, human adult CMs and human pluripotent stem 
cells-derived CMs (hPSC-CMs) 22-25. Recent advances in stem cell biology have 
greatly increased the efficiency of cardiac differentiation of human pluripotent stem 
cells (hPSCs)26,27. Highly pure populations of spontaneously contracting hPSC-
CMs can be robustly and reliably generated at a relatively low cost26,28,29. Recent 
studies have shown that hPSC-CMs resembles many key characteristics of 
functional human CMs including expressions of sarcomeric proteins, exhibiting 
cardiac calcium transient and action potentials30-32. As a result, hPSC-CMs are 
now widely used to study cardiac physiology and pathophysiology in vitro28,33,34. 
Recent studies have focused on disease specific human iPSC-CMs’ 




alternatively on myocardial contractility.35-37 However, hPSC-CMs can display a 
relatively immature phenotype lacking distinct cell edges and highly developed 
sarcomeres, making their study difficult with traditional automated edge detection 
technology or sarcomere length measurement.29,38,39 To date, the simultaneous 
assessment of calcium cycling, action potential characteristics, contractile kinetics, 
and force generation has been challenging. Current methodologies geared at 
assessing myocardial contractility of adult CMs typically rely on edge detection 
techniques that directly assess CM shortening40. These approaches require cells 
with clearly defined cellular borders and distinct striations limiting their applicability 
to less mature cell types.39 Likewise, current traction force microscopy (TFM) 
approaches for the measurement of contractile force of single myocardial cells 
require the use of fluorescent microspheres limiting their capacity for use in 
conjunction with other fluorescently based physiological assays. To address these 
limitations, we present a novel method to comprehensively assess the function of 
single human pluripotent stem-cell-derived cardiomyocyte (hPSC-CMs) through 
simultaneous quantitative analysis of contraction kinetics, force generation, and 
electrical activity. We demonstrate that statistical analysis of movies of contracting 
hPSC-CMs can be used to quantify changes in cellular morphology over time and 
compute contractile kinetics. Using a biomechanical model that incorporates 
substrate stiffness, we calculate cardiomyocyte force generation at single cell 
resolution and validate this approach with conventional traction force microscopy. 




the simultaneous analysis of contractility and calcium handling or action potential 
morphology. Accordingly, our approach has the potential for broad application in 
the study of cardiac disease, drug discovery and cardiotoxicity screening. 
 A promising strategy for treating the loss of myocardium due to an ischemic 
insult is to replace the damaged CMs with healthy ones. Several preclinical and 
clinical studies have used different candidate cell types for cardiac repair and 
restoration purposes with a varying degree of success38,41-43. hPSC-CMs have 
been shown as a promising candidate for cell therapy approach to repair injured 
and failing hearts5,44. However, one major hurdle for using hPSC-CMs in clinical 
applications is the fact that they exhibit a relatively immature phenotype. A 
significant limitation of hPSC-CMs is that unlike adult myocardial cells in vivo, 
hPSC-CMs cultured in vitro maintain an immature metabolic phenotype where 
majority of ATP is produced through aerobic glycolysis instead of oxidative 
phosphorylation in the mitochondria30,38,45,46. Little is known about the underlying 
signaling pathways controlling hPSC-CMs’ metabolic and functional maturation. In 
this study, we aim to define the signaling molecules controlling CMs’ metabolic 
pathway selections and device a strategy to improve CM metabolic and functional 
maturation. To address this, we cultured hPSC-CMs in different media 
compositions including glucose-containing media, glucose-containing media 
supplemented with fatty acids, and glucose-free media with fatty acids as the 
primary carbon source. We found CMs cultured in the presence of glucose utilize 




on oxidative phosphorylation for energy productions. Hypoxia-inducible factor 1-
alpha (HIF1α) and its target lactate dehydrogenase A (LDHA) were aberrantly 
upregulated in CMs cultured in the presence of glucose and corrected by glucose 
deprivation. Small molecule inhibition of HIF1α or LDHA resulted in switching from 
aerobic glycolysis to oxidative phosphorylation. This metabolic shift was 
accompanied by an increase in mitochondrial content and cellular ATP levels. 
Likewise, functional gene expressions, sarcomere length and contractility were 
improved by HIF1α/LDHA inhibition. These findings provide key insight into 
molecular control of hPSC-CMs’ metabolism and may be used to generate more 
physiologically mature CMs for drug screening, disease modeling and therapeutic 
purposes.  
 Then, by combining the novel methodology for quantifying CM contractility 
and the insights on how metabolism can impact CM functions, we investigated the 
effect of glucose cultures on cellular responses to ischemia reperfusion injury in 
vitro. We performed comprehensive functions characterization of CMs exposed to 
hypoxia and discovered that hPSC-CMs respond to in vitro hypoxic injuries in a 
glucose dependent manner. These findings confirmed our earlier observation that 
metabolic pathway utilization controls CMs’ physiological and functional responses 
to stress. We then used the coverslip model of in vitro IR injury to mimic the 
obstruction of flow and reduction in nutrient and oxygen supplies seen during MI 
in vivo. We showed that coverslip ischemia induces cell death and apoptosis in 




dependent on the stiffness of substrates CMs are cultured on, but independent 
from the presence of glucose. The insights gained from this study provided the 






CHAPTER TWO: INTEGRATED ANALYSIS OF CONTRACTILE KINETICS, 
FORCE GENERATION, AND ELECTRICAL ACTIVITY IN SINGLE HUMAN 







Advanced heart failure represents a leading cause of mortality and 
morbidity in the developed world. The clinical syndrome results from an inability of 
the cardiac output to meet the metabolic demands of affected individuals. Most 
commonly this results from a loss of myocardial cell viability or function47-49. CMs, 
the basic functional unit of the myocardium, produce force by shortening and 
thickening during each contractile cycle to generate the forward flow of blood. In 
vitro, myocardial function has been studied at the single cell level or by myocardial 
muscle constructs as a surrogate for in vivo myocardium 50,51. The use of adult 
CMs isolated from the myocardium of adult rodent and other animals for in vitro 
studies of cardiac physiology and pathophysiology has been an established 
method since the 1970s 52. As a result, most techniques used to quantify the 
contractility of CMs have been optimized for cells with distinct edges and highly 
developed sarcomeres. 
Recent advances in stem cell biology have greatly increased the efficiency 
of cardiac differentiation of human pluripotent stem cells26. Human pluripotent stem 
cell derived cardiomyocytes (hPSC-CMs) are now widely used for in vitro studies 
33,34,53 and as cell sources for regenerative cardiovascular medicine51,54. However, 
hPSC-CMs display a relatively less mature phenotype and often lack distinct cell 
edges and highly developed sarcomeres, making the study of their contractility 
with traditional techniques difficult. This has prompted a number of laboratories to 




has been made in this regard, the goal of culturing fully mature human CMs from 
hPSC-CMs remains elusive, highlighting the need for novel methods to functionally 
characterize CMs at different developmental states. 
Two widely used methods to quantify contractile kinetics of adult CMs are 
edge detection and sarcomere length measurements, both derivatives of the 
change in cell shape during contraction40,56. Edge detection technology relies on 
automatically detecting changes in the position of the longitudinal edges of a CM 
over time. This technology is used in fields as varied as oceanographic satellite 
image analysis to face recognition technology 57. Accordingly, its application must 
be optimized for the scale, clarity, and orientation of the images being analyzed. 
Commercially available edge detection tools used to study CMs, for example, have 
been optimized to detect the outer edges of horizontally aligned isolated adult rod-
like CMs that are either in suspension or attached to glass 40. These tools are 
therefore not ideal for the assessment of hPSC-CMs with indistinct borders. 
Moreover, glass is not an ideal substrate for CMs when studying their contraction 
kinetics as the stiffness of glass far exceeds the force generated by contracting 
CMs. Alternative approaches for the quantification of contractility of adult CMs 
include assessment of the change of sarcomere length over time. This approach 
requires the presence of distinct sarcomeres 56 and is therefore not very well suited 
for the study of hPSC-CMs. 
Several approaches have been recently described for analyzing motion in 




These approaches include motion vector analysis after manual segmentation 58, 
block-matching algorithms combined with motion vector analysis 59,60, or the 
evaluation of the correlation between intensity vectors of frames within a movie 61 
to yield a unit-less or dual-peaked curve representing the beating signal. These 
approaches however do not directly allow for the quantitative assessment of 
fractional shortening and force generation kinetics, key features of cardiomyocyte 
physiology. CM force generation has previously been assessed by a number of 
different methods including fluorescent microsphere-based traction force 
microscopy, atomic force microscopy, and micropost deformation measurements 
62-64. These techniques are highly specialized, require advanced instrumentation, 
and cannot be easily combined with optical measurements of contractile kinetics, 
measurements of calcium cycling, or action potentials. 
Herein, we present a novel methodology for the quantitative analysis of CM 
contractile kinetics and force generation that can be used in hPSC-CMs as well as 
isolated adult CMs. Our approach is not based on tracking motion of parts of the 
cell but rather on quantifying the total amount of change in cell morphology over 
time. We use a previously well-validated statistical tool to analyze similarity 
between frames in movies of contracting human embryonic stem cell derived 
cardiomyocytes (hESC-CMs) to generate a similarity matrix. This matrix 
represents the change in cell morphology over time and is used to compute the 
contractile kinetics of hESC-CMs. We combine this methodology with a 




CMs deform a flexible substrate. We validate this approach in human stem cell 
derived CM as well as in murine adult myocardial cells at single cell resolution as 
well as in myocardial clusters. We further demonstrate our ability to detect subtle 
changes in the contractile kinetics and force generation of hESC-CMs in response 
to pharmacological intervention with isoproterenol and verapamil. Furthermore, we 
show that our methodology can be applied simultaneously with other single cell 
physiological assays for the quantification of calcium cycling and action potentials. 
Finally, we show the utility of this method in assessing the cardiotoxicity of drugs 






Morphologic Similarity Measure to Produce Contraction Curves 
The goal of the present study is to generate a high throughput unbiased and 
robust methodology for the analysis of contraction kinetics and force generation of 
stem cell derived CMs that is compatible with fluorescence-based calcium cycling 
and action potential assessment. We therefore performed directed differentiation 
to generate hESC-CMs. On days 13-20 of in vitro differentiation, CMs were 
dissociated into single cell suspension and plated on a PDMS flexible substrate at 
single-cell density. By culturing these CMs on the PDMS flexible substrate, the 
cells could contract against strain.62 After 14 days of culture on the flexible 
substrate, cells were visualized in a temperature and CO2 controlled chamber by 
DIC imaging as described in the Materials and Methods. We acquired movies of 
the contracting cells at a temporal resolution of at least 100 frames per second 
(fps). 
As an example to illustrate our novel methodology, a 300-frame movie at 
100 fps of a single hESC-derived rod-like CM undergoing a single contraction cycle 
was analyzed. The CM is in a pre-contractile relaxed state between frames 1 (F1) 
and F140, shortens between F140 and F165, before returning to the baseline-
relaxed state. We first sought to determine the change in cell morphology during 
these 300 frames. We therefore quantitatively assessed the similarity of F1 to 
every other frame in the movie by performing a pairwise similarity comparison (SC) 




the SC for all pairs of frames captured at times i and j (i ≠ j). Each pair of frames is 
compared based on the color intensity of spatially corresponding pixels defined by 
an intensity function Ix,y,t’ where x and y are integers defining the coordinates of 
a given pixel in a particular frame and t’ is an integer corresponding to the time of 
capture of the frame. The intensity function values of all the pixels in each frame 
are summated over N, where N is the total width * total height of each frame. The 
similarity function is commutative such that SCi,j = SCj,i. Furthermore, SCi,j = 1 if 
i == j.  Thus, SC is defined as having a value between 0 and 1 where the more 
similar two frames are to each other, the closer their SC value is to 1. We plotted 
the pairwise SC value of F1 against every other frame which yielded a preliminary 
analysis of the contraction cycle (Figure 1B). The SC of the relaxed frame F1 vs. 
the pre-contractile frames F2 through F140 resulted in relatively high SC values 
(highly similar). The SC values of F1 vs. the contractile frames (F141-F165) 
dropped dramatically (highly dissimilar). And finally the SC values of F1 vs. the 
post-contractile frames returned to the high baseline value (again highly similar). 
To visually display the outcome of the SC analysis, we used Fiji to calculate 
the digital differences between F1 and the pre-contractile frame F100. Spatially 
corresponding pixels that have a similar intensity result in a dark pixel, 
corresponding pixels that have a less similar intensity result in a lighter pixel. This 
calculation resulted in an essentially black image with a faint apparently random 
white speckled background and an associated SC of 0.923 because these two 




although not identical. (Figure 1C). Digital difference of F1 and the contractile 
frame F165 resulted in a high contrast black and white image with an associated 
SC of 0.301 indicating a clear signal because the change in cell morphology has 
resulted in a change of the intensity of many pixels compared to the corresponding 
pixels in the other frame (Figure 1D). Finally, digital difference between F1 and 
the post-contractile frame F300 again yielded an essentially black image with a 
faint speckled white background and an associated SC of 0.917 (Figure 1E). 
In contrast, pairwise analysis of contractile frame F165 to every other frame 
resulted in an inverted appearing contractile cycle (Figure 1F) The SC value of 
F165 vs. the relaxed frames was very low (highly dissimilar), became progressively 
higher (more similar) for the contractile frames, and dropped again for the post-
contractile frames. Likewise, the digital difference of F165 vs. the pre-contractile 
frame F100 was a high contrast image with an associated SC of 0.294 (Figure 
1G). Digital difference of F165 vs. the contractile frame F166 was essentially black 
with a faint white speckled background and an associated SC of 0.930 (Figure 
1H). And finally, digital difference of F165 vs. the post-contractile frame F300 was 
again a high contrast black and white image with an associated SC value of 0.302 
(Figure 1I).  
To capture all the similarity data in the movie, we then performed a pairwise 
comparison of each frame in Movie S1 vs. every other frame to produce a similarity 
matrix of 300 rows by 300 columns where each row of the matrix contains a series 




was then plotted as a series of similarity curves in a three-dimensional graph 
(Figure 2A). Sample portions of the 300x300 matrix are displayed (Figure 2B) 
with the left panel showing the pairwise comparison of pre-contractile frames F1-
F5 vs. F1-F5 (all highly similar), the middle panel showing F1-F5 vs. contractile 
frames F163-F168 (highly dissimilar), and the right panel showing F1-F5 vs. post-
contractile frames F210-214 (all highly similar again). 
 To obtain a more physiological assessment of the CM contraction cycle we 
used the average of the similarity curves of pre-contractile frames (Figure 2C) as 
the baseline for the maximally relaxed state. We defined the pre-contractile period 
as the terminal 15% of the inter-contraction interval as determined by a rolling 
linear regression analysis of all frames (Figure 3A,B). Next, we averaged these 
similarity curves to obtain the Baseline Adjusted Similarity Comparison (BASiC) 
curve. We then normalized the maximum and minimum SC values to manually 
measured cell length at end-diastole and peak systole. This allowed us to generate 
a normalized contraction curve of CMs with percent cell length plotted against time 
(Figure 2D). Manually measured cell length measurements were highly similar 
between independent observers with a mean difference of 0.3µm (95% limits of 
agreement -1.8 µm to 1.2 µm; Figure 3C).  
 We then empirically validated this novel quantitative analysis and 
demonstrated that the BASiC-generated cell length curves correlate with 
contraction curves generated by manual cell length measurement, automated 




correlation coefficients of greater than 0.98 in adult murine CMs (Figure 4A,C,E). 
We then repeated a similar type of analysis on rod-like hESC-CMs and 
demonstrated that BASiC-generate cell length curves were highly correlated with 
manual cell length curves with Pearson’s correlation coefficients of 0.98 (Figure 
4B,D,E). Of important note, automated edge detection methods could not generate 
usable contraction curves for hESC-derived CMs due to the relatively low contrast 
edges of these cell types, highlighting the need for an automated alternative to 
edge detection. Similarly, these cells do not have well developed sarcomeres. 
 In addition, we analyzed the similarity between contraction curves 
generated by BASiC and manual measurements of irregular shaped hESC-CMs 
cultured on PDMS (i.e., non rod-like), hESC-CM clusters cultured on PDMS or in 
suspension, and hESC-CM monolayers on polystyrene (Figure 5A-I). We found 
Pearson’s correlation coefficients above 0.95 in all these conditions, indicating the 
applicability of BASiC to analyze CM contractility in variable setups. Further testing 
revealed that differences in frame rate, light intensity and resolution during image 
acquisition had a minimal impact on BASiC analysis (Figure 5J-N).  
Mechanical Model for Quantification of Force Generation  
We then sought to quantify the force generated by individual CMs by 
traction force microscopy (TFM), a well-validated methodology used to estimate 
the force generated by individual CMs 62. In traditional TFM cells are plated on 
flexible substrates with fluorescent microspheres attached to the surface of the 




attached fluorescent microspheres. Since the stiffness of the substrate is known, 
it is possible to estimate the contractile force required for its deformation from the 
movement of the fluorescent microspheres. Since cell shortening is not measured 
directly but rather inferred from microsphere movement, this approach relies on 
the assumption that microsphere movement and cell shortening are directly 
correlated. To test this underlying assumption, we cultured hESC-CMs on flexible 
PDMS substrates embedded with fluorescent microspheres. Cell shortening 
correlates closely with microsphere movement validating this assumption (Figure 
6A). We then calculated the force generated by single contracting rod-like CMs 
from the microsphere movement (Figure 7A,E,F) with standard techniques and 
obtained results similar to previous reports 62,70. An important limitation of standard 
TFM approaches is the use of fluorescently labeled microspheres limiting their 
compatibility for use in conjunction with fluorescent-based physiological assays 
such as optical mapping of calcium cycling and action potential. To address this 
limitation and capitalize on the power of our novel methodology, we utilized a 
mechanical model based on cell dimensions, cell shortening, and growth substrate 
properties to calculate the force generated by single contracting myocytes without 
the use of fluorescent microspheres (described in detail in Experimental 
Procedures). A direct comparison of both TFM methodologies (with and without 
microspheres) revealed highly similar force curves with a mean Pearson’s 
correlation coefficient of 0.96 (Figure 7B,C). Likewise, the mean difference in peak 




Figure 7D). We then repeated these experiments with irregular-shaped hESC-
CMs and CM clusters on PDMS and again found highly similar force curves with 
average Pearon’s correlation coefficients above 0.95. The ratio of peak force 
calculated by TFM with BASiC over peak force calculated by TFM with 
microspheres was 1.02 ± 0.04 for CM clusters and 1.40 ± 0.15 for irregularly 
shaped CMs (Figure 6B-G). 
Quantification of pharmacotherapy effects 
 To evaluate the sensitivity of our novel methodology in detecting small 
changes in the contractile behavior of individual hESC-CMs, we examined the 
dose response of two bioactive agents widely used in cardiovascular research. 
Verapamil is an L-type calcium channel blocker that’s been shown to decrease CM 
contractility 71,72. Conversely isoproterenol is a non-selective beta-adrenergic 
agonist 73. hESC-CMs were paced with field stimulation at a rate of 1.2 Hz and 
movies of single rod-like CMs contracting on PDMS gels were captured at baseline 
and after treatment with 10 nM and 100 nM of verapamil or isoproterenol. CM 
contraction curves were then generated as described above. Calcium cycling was 
also concurrently assessed via fluorescence imaging with the calcium dye Fluo-
4AM. In a control experiment, the effect of Fluo-4AM on hESC-CM contractility was 
analyzed over a period of 60min and no significant differences in contractility were 
found (Figure 8A-G). In an additional control experiment with hESC-CMs, the 
calcium dye intensity remained stable over a period of 60 min (Figure 8H). 




as assessed by fluorescent signal, fractional shortening and force curves (Figure 
9A). Quantitative analysis of the contraction kinetics and calcium cycling revealed 
negative inotropic and lusitropic effects on CM contractility by the administration of 
verapamil with a significant reduction in maximum shortening velocity, peak 
contractile force, maximum relengthening velocity, and calcium transient amplitude 
(Figure 9B-G). In contrast, treatment with isoproterenol resulted in progressive 
positive inotropic and lusitropic effects with a significant increase in maximum 
shortening velocity, peak contractile force, and maximum relengthening velocity. 
We also observed significant decreases in time to 50% peak shortening and time 
to 90% relengthening (Figure 10). We analyzed the responses to these 
pharmacological interventions as the average fold change of multiple cells. As 
expected due to the heterogeneous nature of hESC-CMs, there was some degree 
of variability in the functional characteristics of these myocytes at baseline and in 
response to verapamil (Figure 8I-N) and isoproterenol (Figure 11A-F). 
Subsequently, isolated adult mouse CMs field-stimulated at 1Hz were treated with 
100nM isoproterenol, contraction curves were generated with BASiC, and a 
significant positive inotropic effect was again observed. (Figure 11G-M). 
Fluorescent transmembrane voltage reporters have been previously used 
to study toxic electrophysiological changes after treatment with anti-arrhythmic 
drugs such as dofetilide, a blocker of the rapid component of the delayed rectifier 
current (IKr). Prior work has demonstrated that dofetilide prolongs the cardiac 




studies to date, however, have examined the effect of such drugs exclusively on 
action potential characteristics 75,76. We hypothesized that by concurrently 
examining CM contractility and action potential characteristics, we would be able 
to better assess cardiotoxicity of such commonly used drugs. Movies of single rod-
like CMs contracting on PDMS gels were captured at baseline and after treatment 
with 10nM dofetilide. Action potential morphology was concurrently assessed via 
fluorescence imaging with the transmembrane voltage reporter FluoVolt 77,78. At 
baseline, hESC-CMs exhibited regular intervals between action potentials and 
contractions with consistent peak amplitudes even in the absence of field 
stimulation (Figure 12A). Upon treatment with the arrhythmogenic agent dofetilide 
however, cells exhibited multiple toxic responses including early 
afterdepolarizations (Figure 12B), irregular interbeat intervals (IBI; Figure 12C) 
and irregular contraction peak amplitudes (PA; Figure 12D). We then quantified 
the coefficient of variation (COV) for both the IBI and PA for the cells before and 
after dofetilide treatment and compared the measurements for action potential 
profile and the contractility profile. Although some of the toxic effects were 
identified in both the action potential and contraction profiles, others were only 
apparent in the contraction curve highlighting the need to examine excitation-







The advent of human induced pluripotent stem cell technology coupled to 
advances in directed cardiac differentiation protocols has opened new avenues for 
the study of human myocardial physiology and pathophysiology. Recent studies 
have focused on disease specific human induced PSC-CMs’ electrophysiology 
and calcium cycling properties for cardiac disease modeling or alternatively on 
myocardial contractility 35-37,79. To date, the simultaneous assessment of calcium 
cycling, action potential characteristics, contractile kinetics, and force generation 
has been challenging. Current methodologies geared at assessing myocardial 
contractility of adult CMs typically rely on edge detection techniques that directly 
assess CM shortening 40 or the change in sarcomere striations over time 56. These 
approaches require cells with clearly defined cellular borders and distinct striations 
limiting their applicability to less mature cell types 39. Likewise, current TFM 
approaches for the measurement of contractile force of single myocardial cells 
require the use of fluorescent microspheres limiting their capacity for use in 
conjunction with other fluorescently based physiological assays. Other approaches 
including optical flow analysis yield a unit-less or dual-peaked curve rather than 
standard fractional shortening and force generation curves, 
Herein, we present a novel methodology that provides a flexible tool for the 
study of contraction kinetics of single myocardial cells at different stages of 
maturation cultured on substrates with tunable stiffness. Our approach is based on 




characterized flexible substrates and yields a standard contraction curve of hPSC-
CMs contracting against strain. Critically this allows for the generation of fractional 
shortening curves and the calculation of contraction and relaxation velocities 
similar to those used in many studies of adult cardiomyocytes. We then incorporate 
the mechanical properties of the growth substrate to quantify the kinetics of force 
generation at single cell resolution and in myocardial clusters. We demonstrate 
that our novel approach is ideally suited for rod-like cells and myocardial clusters 
and has a high degree of correlation with standard TFM that requires the use of 
fluorescent microspheres. Since we do not use fluorescence for the assessment 
of force generation, our approach is readily suitable for the concurrent assessment 
of the kinetics of force generation along with calcium cycling and action potential 
at single cell resolution. An important advantage of the simultaneous assessment 
of force generation and electrophysiological characteristics is the ability to 
unequivocally determine if a pathophysiological process results in 
electromechanical dissociation. Since our approach yields fractional shortening 
curves, it should also allow for an easier comparison of contractile phenotype 
between hPSC-CMs and adult CMs in maturation studies, disease modeling and 
pharmacological experiments. Importantly, our method is economical and widely 
applicable since it only requires movie microscopy without the need for highly 
specialized hardware or genetically engineered cell lines. 
In proof-of-principle experiments, we examined the response of hESC-




cardiovascular research. Single CMs exhibited significantly reduced calcium 
transient amplitude associated with a negative inotropic response to treatment with 
the L-type Ca2+ channel blocker verapamil. These results are in accordance with 
previous reports from hPSC-CM based tissue engineered heart tissues 71,80, 
embryoid bodies 72, and hPSC-CM monolayers 81. Likewise, we observed a dose-
dependent positive inotropic response to isoproterenol. Prior studies using hPSC-
CMs have found a variable inotropic response to isoproterenol. While some studies 
show a significant inotropic response in EBs and single hPSC-CMs 60,82,83, other 
studies show transient or no response in EBs and engineered heart tissue 71,73,84,85.  
Over the past decades numerous drug development projects have been 
halted by concerns over cardiotoxicity. Since significant differences exist between 
humans and rodents, hPSC-CMs have been suggested as a promising alternative 
to rodent adult CMs. Several studies using hPSC-CMs for cardiotoxicity screening 
have been performed with different readouts of toxicity such as increased action 
potential duration and the occurrence of early afterdepolarizations 76,86. We 
demonstrate our ability to rapidly detect drug-induced cardiac toxicity by assessing 
contractility and action potential simultaneously. Our finding that excitation-
contraction coupling may be perturbed under toxic conditions suggests that 
simultaneously assessing action potential characteristics and contractile behavior 
may improve the sensitivity of drug-induced cardiac toxicity screening. 
Heart failure represents a major unmet clinical need. Despite the recent 




remains the cornerstone of treatment for heart failure. Our novel methodology 
should have broad applications in the study of normal and diseased myocardial 
contractile physiology and should be suitable for drug discovery and toxicology 
testing using normal or diseased stem cell derived myocardial cells. 
EXPERIMENTAL PROCEDURES 
Generation of Flexible Culture Substrates 
Flexible substrates were generated by adding 50µL of Sylgard 527 
Polydimethylsiloxane (PDMS), parts A and B mixed at a 1:1 ratio, onto a Fluorodish 
(WPI) and curing at 60°C for 6 h.87 Subsequently the Fluorodishes were UV-
sterilized and coated with Matrigel (BD Biosciences) prior to cell seeding. 
Human Embryonic Stem Cells Maintenance And Cardiac Differentiation 
Human embryonic stem cells (hESCs) from the lines HUES-9 and HES-3 
NKX2-5eGFP/w were cultured with mTESR-1 growth medium (StemCell 
Technologies) in polystyrene plates coated with Matrigel (BD Biosciences) as 
previously described 26. hESCs were mechanically passaged every 5 days after 
reaching confluence.  
Cardiac differentiation of hESCs was performed using a previously 
established protocol.26 Briefly, hESCs were treated with 10 μM of CHIR99021 
(Stemgent), a GSK-3β inhibitor, at day 0 of differentiation followed by media 
change at day 1. The cells were then treated with 5 μM of IWP4 (Stemgent), a Wnt 
Inhibitor, at day 3 of the differentiation and followed by media change at day 5. For 




supplemented with Gem21 NeuroPlex without Insulin (Gemini) was used. After day 
7, media change was performed every 72 h with RPMI Medium 1640 (Life 
Technologies) supplemented with Gem21 NeuroPlex (Gemini) (CM culture media). 
Spontaneous contractions were first observed starting at day 8 of differentiation, 
increased through day 15, and remained stable thereafter. 
Fluorescence Activated Cell Sorting (FACS) 
The simultaneous DIC imaging with fluorescent calcium imaging 
experiment was performed with GFP+ HES-3 NKX2-5eGFP/w cells. Cells were 
isolated with a FACS protocol as previously described 88. 
Dissociation and Plating 
Beating CMs were dissociated into single cell suspensions after 15-20 days 
of differentiation as previously described 89. Single hESC-CMs were seeded on 
Matrigel-coated Fluorodishes at 2k-6k cells cm-2. Single contracting CMs and CM 
clusters growing on PDMS substrates for more than 2 weeks were chosen for drug 
treatment and image acquisitions. To obtain hESC-CM clusters in suspension, 
beating CMs were treated with 0.05% Trypsin (Life Technologies) for 5 min, after 
which the reaction was neutralized with 10% fetal bovine serum (Life 
Technologies). 
Confocal Imaging and Drug Treatment  
Single contracting CMs and CM clusters cultured on flexible substrates, CM 
clusters in suspension, and CM monolayers on polystyrene were imaged in CM 




(TMC). Cells were placed inside a climate control chamber at 37°C with 5% CO2 
(Pathology Devices) 30 min prior to the start of experiments. For the verapamil and 
isoproterenol experiments, the cells were field stimulated with 10 V at 1.2 Hz using 
the RC-37WS perfusion insert with electrodes (Warner Instruments) connected to 
the C-Pace EP stimulator (Ion Optix). Movie recording of CM contraction cycles 
was performed with Differential Interference Contrast (DIC) microscopy using a 
488nm or 647 nm laser. Movies of CMs displaying at least 5 contraction cycles 
were recorded at baseline and then 5 min after each treatment. Cells were treated 
with (±)-Verapamil hydrochloride (Sigma), (−)-Isoproterenol hydrochloride (Sigma) 
or Dofetilide (Sigma) as described in Results. For calcium imaging, 0.5 μM of Fluo-
4AM (Life Technologies) was added to the CM culture media 10 min prior to image 
acquisition. For action potential imaging, FluoVolt Membrane Potential Kit (Life 
Technologies) was used at a dilution of 1:1000 according to the manufacturer’s 
protocol. Both fluorescence and DIC channels were recorded concurrently for 
multiple contraction cycles.  
Data Analysis and Display 
The Nikon Elements software package and Fiji were used for movie file 
conversions.90 Movies were cropped using Fiji to isolate the contracting CM from 
neighboring cells and cellular debris. Movies were loaded into Visible software 65-
69 (Reify Inc.) to generate a similarity matrix of n rows by n columns, where n is the 
number of frames in the movie. Analysis of the similarity matrix was performed in 




from a single video were averaged by matching the start of the contractions. Curve-
fitting was applied to this averaged curve to obtain accurate measurements of 
maximum shortening and relengthening velocities, and time to 50% shortening and 
90% relengthening respectively. The three-dimensional matrixes were generated 
using GNU Octave and MATLAB (MathWorks). 
Normalization of Contraction Curve 
The baseline adjusted similarity comparison (BASiC) index and frame 
numbers of the BASiC contraction curve were normalized to respectively 
percentage of maximum cell length and time. For this purpose, manual cell length 
measurements were performed in Fiji90 over the longitudinal axis of the cell at the 
last frame prior to contraction (lengthmax) and the peak shortening frame (lengthmin). 
These manual measurements were used in the following equation to normalize 
BASiC to cell length: 
𝐿𝑒𝑛𝑔𝑡ℎ = 𝑙𝑒𝑛𝑔𝑡ℎ  (1 −
1 − 𝑆𝐶 𝑆𝐶⁄
𝑁𝑅
) 
The SCmax was defined as the average SC of the previously selected pre-
contractile frames. SCmin is the SC value at the peak shortening frame. The 
Normalization Ratio (NR) is a measure of the relative change in SC compared to 
the relative change in length during a contraction and is defined as: 
𝑁𝑅 =
1 − 𝑆𝐶 𝑆𝐶⁄
1 − 𝑙𝑒𝑛𝑔𝑡ℎ 𝑙𝑒𝑛𝑔𝑡ℎ⁄
 
Traction Force Microscopy with Fluorescent Microspheres 




calculate the contractile force of CMs 62,91. Briefly, sulfate modified fluorescent 
microspheres (Invitrogen) were placed in sterile water at a volume ratio of 1:200, 
sonicated for 30 min, and coated onto PDMS substrates treated with 1 mg ml-1 
Dopamine hydrochloride (Sigma). The substrates were then UV-sterilized and 
coated with Matrigel (BD Biosciences). CMs were seeded onto the substrates and 
cultured for 14 days. Movies of single CMs and CM clusters contracting on the 
substrates were recorded in both fluorescent and DIC channels. Images of CMs 
and the microspheres were extracted from the movies at different contraction 
frames. The software package TractionForAll 92 was used to calculate the force 
generated by CMs. DIC images of the cells were used for BASiC analysis as 
described in Results.  
Traction Force Microscopy without Fluorescent Microspheres 
Contractile forces generated by shortening CMs were calculated in 
MATLAB based on the contractility curve generated with BASiC, dimensions of the 
CM and mechanical properties of the PDMS substrate 87. Variable input for the 
MATLAB script is the width of the cell in cm, the length of the cell (in the direction 
of contraction) in cm, and the amount of cell shortening in cm. The Young’s 
modulus of PDMS substrates was 5 kPa for all experiments. To calculate 
contractile force generated by cardiomyocytes on flexible substrates with a static 
mechanical model we make the following assumptions: 1.) The cell is rectangular, 
and contracts along one of its directions, without any lateral impediment. 2.) The 




cell is attached. 3.) The shearing forces are symmetric with respect to the center, 
that is, they point in opposite directions and cancel in the aggregate. 4.) The 
shearing traction distribution is assumed to be governed by Boussinesq’s law 
 , where  is the half-length of the cell.  
For the 5kPa PDMS used in these experiments the Poisson’s ratio ( ) was 
set to 0.5, the mass density of the gel (𝜌) was set to 1.08 g/cm3, and the shear 
wave velocity (𝐶 ) was set to 200.8 cm/s. The shear modulus ( ) was then 
calculated as:  
𝐺 =  𝜌𝐶   
We sub-divide the rectangular cell of dimensions  into narrow 
rectangles of width . Consider a rectangular load of dimension  and 
magnitude applied at the free surface of the half-space, with its sides oriented 
parallel to the  axes. It can be shown that the horizontal displacement at the 
center of the load is given by 
,  (1)   
where 
     
 , 




















u xox  
 
 
2 2 1 11
1 2 1/20 0 2 2
, sinh sinh
b a dxdy b a
I a b a b
a bx y







2 2 3/20 0 2 2
, sinh
b a x dxdy a








We consider next the case of contact stresses underneath the 
cardiomyocyte that follow the Boussinesq law: 
          
The displacement elicited by each narrow slit at any location is then 
evaluated via equation (1), scaling the intensity q0 of the load so that the total 
elongation of the cell equals the cell’s length (i.e. unit strain). Finally, the force 
needed to accomplish that strain is computed as 
. 
The MATLAB script used to do these calculations is available upon request.  
Isolation of Adult Mouse Cardiomyocytes 
Mouse hearts from adult C57BL/6 mice were perfused with a Langendorff 
apparatus as previously reported93. Briefly, a 12-gauge mouse feeding needle was 
inserted into the aorta and the heart was subsequently perfused for 18 min at a 
rate of 1 ml min-1 with Tyrode Buffer supplemented with 5.5 mM D-(+)-Glucose 
(Sigma), 5mM Taurine (Sigma), 10 mM 2,3-Butanedione monoxime (Sigma),  0.5 
mg ml-1 collagenase A (Roche) and 0.5 mg ml-1 collagenase B (Roche) at 37°C. 
Next, the heart was minced with micro dissecting forceps to dissociate the tissue 
into single CMs. The cell solution was transferred to Tyrode Buffer supplemented 
with 1.2 mM CaCl (Sigma) and 5.5 mM D-(+)-Glucose (Sigma) and placed in a 



























with sharply defined membranes were selected for imaging. All animal care and 
experimental procedures were approved by the Massachusetts General Hospital 
Institutional Animal Care and Use Committee. 
Edge Detection 
Edge detection was performed by plotting a line intensity profile over the 
longitudinal axis of the CM in Fiji 90 where the edge contrast for both the left and 
right edge was optimal, similar to commonly used edge detection software 94. The 
cell edge was defined as the location of the mean of the maximum and minimum 
intensity value in the high contrast region of the line profile at the cell edge. The 
cell length over time was subsequently determined by calculating the distance 
between the location of the left and right edge of the cell in each frame of a movie. 
Sarcomere Length Measurement 
Sarcomere length measurement was performed by plotting a line intensity 
profile in Fiji 90 over the longitudinal axis of the CM to cover at least 10 sarcomeres, 
similar to commonly used sarcomere length measurement software 56. Due to the 
alternating dark and light A- and I-bands, the line intensity profile had a sinusoidal 
appearance. The distance between at least 10 peaks was divided by the number 
of peaks to reflect the average sarcomere length.  
Statistical Analysis 
All data was analyzed using GraphPad Prism 6 software (GraphPad 
Software Inc.) and presented as means ± SE from the number of cells indicated in 




the Kolmogorov-Smirnov test. Contraction kinetics and force generation data were 
compared using Repeated Measures ANOVA followed by Bonferroni post-test 
analysis for multiple comparisons. Coefficient of variation data were compared 
using paired t-test. Differences were considered significant at P<0.05. 
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Figure 1. Pairwise similarity comparison of frames in a movie of a 
contracting CM. (A) The equation to calculate similarity comparison (SC) between 
2 frames. Each pair of frames is compared based on the intensity (grayscale value) 
of pixels in the same location of the two frames. The intensity is defined by the 
function Ix,y,i where x and y define the coordinates of a given pixel in frame i. The 
values of all the pixels in each frame are summed over the frame area (N). The 
similarity function is commutative such that SCi,j = SCj,I. The SC of two identical 
frames is defined as 1. (B) A plot of SCs of frame F1 vs. every other frame of Movie 
S1. Blue, red and green arrows refer to the SCs for F1 vs. F100, F165, and F300, 
respectively. (C) The digital difference between the relaxed frame F1 (top panel) 
and the pre-contractile frame F100 (middle panel) is displayed in the bottom panel 
with the associated SC value. (D) The digital difference between F1 (top panel) 
and the contractile frame F165 (middle panel) is displayed in the bottom panel with 
the associated SC value. (E) The digital difference between F1 (top panel) and the 
post-contractile frame F300 (middle panel) is displayed in the bottom panel with 









Figure 2. Generation of contraction curve from similarity matrix. (A,B) Three-
dimensional graph displaying the similarity matrix of Movie S1 where X and Y-axes 
display frame numbers and the Z axis displays the SC value. The superimposed 
black lines display the SC plot of F1 and F165 compared to every other frame 
(Figure 1B,F). The blue, red, and green planes map areas of the three-
dimensional graph to the associated portion of the matrix. (C) Three-dimensional 
graph of the selected pre-contractile SC curves. (D) Baseline adjusted similarity 
comparison (BASiC) normalized to cell length and time for the generation of a 









Figure 3. Selection of pre-contractile frames and reliability of cell length 
measurements. (A) Graph of averaged SC (aSC) of all frames over frame number 
for Movie S1. Red crosses mark the points of maximum contraction (local 
minimum). (B) Slope (∆aSC/∆Frame) of the rolling five-point linear fit line. The 
inter-contractile interval is marked by dashed red lines and defined as frames with 
a deviation of slope from 0 of less than 5% of the minimum slope as indicated by 
red lines. Frames in the terminal 15% of the inter-contractile interval are defined 
as pre-contractile marked by the green shaded area. The dotted black lines show 
the correlation between maximum contraction points in aSC and slope. (C) Bland-
Altman graph of average cell length measurement of two observers plotted against 
the difference between measurements. Cell length measurements between 
observers were highly similar with a mean difference (dashed line) of 0.17µm (not 
significantly different from 0; P = 0.45) and 95% limits of agreement (dotted lines) 












Figure 4. Validation of contraction curve in isolated adult murine CMs and 
hESC-CMs. (A,B) Comparison of representative isolated murine adult CM and 
hESC-CM in a relaxed (top panel) vs. a contracted (bottom panel) state. Solid 
white lines represent position of cell edges in relaxed state. Dotted white lines 
represent position of cell edges in contracted state. Scale bars, 10 µm. (C,D) 
Contraction curves generated by manual measurement (black line), Edge 
Detection (blue line), sarcomere length measurement (yellow line) and BASiC (red 
line) of the representative murine adult CM and the representative hESC-CM. (E) 
Pearson’s correlation coefficient (Pearson’s r) between contraction curves 
generated by manual measurement (M), Edge Detection (ED), and BASiC (Ba) of 
adult CMs (black bar, n=15 cells from 3 independent experiments) and hESC-CMs 
(grey bar, n=16 cells from 3 independent experiments). Data are represented as 









Figure 5. Validation of BASiC for irregular-shaped CMs, CM clusters, and 
monolayers and different movie acquisition settings. (A-D) Comparison of a 
representative irregular shaped hESC-CM on PDMS, hESC-CM cluster on PDMS, 
hESC-CM cluster in suspension and hESC-CM monolayer on polystyrene in a 
relaxed (top panel) vs. a contracted (bottom panel) state. Solid white lines 
represent position of cell structure edges in relaxed state. Dotted white lines 
represent position of cell structure edges in contracted state. Scale bars, 20 µm. 
(E-H) Contraction curves generated by manual measurement (black line), and 
BASiC (red line) of the representative cell/cluster/monolayer. (I) Pearson’s 
correlation coefficient (Pearson’s r) between contraction curves generated by 
manual measurement and BASiC of cells/clusters/monolayers. n= at least 6 from 
3 independent experiments for all groups. Data are represented as mean ± SE. (J-
M) Four movies of the same hESC-CM monolayer on polystyrene acquired with a 
variety of settings for frame rate, resolution and pixel saturation. Movie 1: 100 fps, 
resolution 2.52 µm/px, oversaturated lighting. Movie 2: 100 fps, resolution 2.52 
µm/px, normal lighting. Movie 3: 55 fps, resolution 2.52 µm/px, normal lighting. 
Movie 4: 30 fps, resolution 1.26 µm/px and normal lighting. (N) Contraction curves 
generated by BASiC of Movies 1-4 acquired under different settings show a high 








Figure 6. Correlation of bead movement and cell movement, and force 
calculations for CM clusters and irregular-shaped CMs. (A) Fluorescent 
microsphere movement accurately translates into CM shortening. Bland-Altman 
graph of average of microsphere movement measurement and CM shortening 
measurement. Microsphere movement and CM shortening correlate closely with a 
mean difference (dashed line) of 0.16% (not significantly different from 0; P = 0.08) 
and 95% limits of agreement (dotted lines) of -0.35% to 0.68%. n = 11 cells from 3 
independent experiments. (B) Plot of contractile force of a hESC-CM cluster 
calculated by Traction Force Microscopy (TFM) using BASiC overlaid with force 
calculated by TFM using fluorescent microspheres (MS). (C) Pearson’s r between 
contraction curves generated by the two methods. n = 11 CM clusters from 3 
independent experiments. (D) Ratio of peak force calculated by TFM with BASiC 
over peak force calculated by TFM with MS. (E) Plot of contractile force of a hESC-
CM cluster calculated by TFM using BASiC overlaid with force calculated by TFM 
using MS. (F) Pearson’s r between contraction curves generated by the two 
methods. n = 6 cells from 3 independent experiments. (G) Ratio of peak force 
calculated by TFM with BASiC over peak force calculated by TFM with MS. Data 











Figure 7. TFM with and without fluorescent microspheres for single cell force 
measurement.  (A) Top panel shows an image of the PDMS surface coated with 
200uM fluorescent microspheres, the yellow outline indicates the outline of the CM 
at its fully contracted state. Bottom panel shows a DIC image of the CM. Scale bar, 
10 μm. (B) Plot of contractile force calculated by TFM using BASiC overlaid with 
force calculated by TFM using fluorescent microspheres. (C) Pearson’s r between 
contraction curves generated by the two methods. n = 11 cells from 3 independent 
experiments. Data are represented as mean ± SE. (D) Bland-Altman graph 
showing average of force measured by TFM using BASiC and TFM using 
fluorescent microspheres plotted against difference in measurements. Mean 
difference (dashed line) and 95% limits of agreement (dotted lines) are indicated. 
n = 10 cells from 3 independent experiments. (E) Microsphere displacement heat 
map (top panel) and vector map (bottom panel) of the CM at its peak contraction 
state compared to its relaxed state. (F) Traction force heat map (top panel) and 










Figure 8. Fluo-4AM effect and signal consistency, and intercell variability in 
response to verapamil. (A) Representative contraction curves of a single hESC-
CM before treatment and 30 min and 60 min after treatment with 0.5µM Fluo-4AM 
(F4) calcium transient indicator. (B-G) Fold change in peak shortening, time to 50% 
peak shortening (TPS50), maximum shortening velocity (-ΔL/Δt), maximum 
relengthening velocity (+ΔL/Δt), time to 50% relengthening (TR50) and time to 90% 
relengthening (TR90) of cells 30 min and 60 min after treatment with 0.5µM Fluo-
4AM compared to baseline. n= 6 cells from 3 independent experiments. (H) Fold 
change in peak intracellular fluorescence signal of hESC-CMs loaded with 0.5µM 
Fluo-4AM. Measurements were taken at 0, 10, 30 and 60 minutes. n= 10 cells from 
3 independent experiments. Data are represented as mean ± SE. (I-N) Intercellular 
variability in contractile characteristics of hESC-CMs at baseline and in response 












Figure 9. Quantitative analysis of CM function in response to verapamil. (A) 
Representative contraction curves of a single field-stimulated hESC-CM treated 
with the L-type calcium channel blocker verapamil. Changes in Fluo-4, AM calcium 
transient indicator intensity (top panel), percentage cell length (middle panel), and 
contractile force (bottom panel) of the cell over time are shown. (B-G) Fold change 
in calcium transient amplitude (∆F/F0), peak force (PF), maximum shortening 
velocity (-∆L/∆t), maximum relengthening velocity (+∆L/∆t), time to 50% peak 
shortening (TPS50), and time to 90% relengthening (TR90) of cells treated with 
10nM and 100nM verapamil compared to baseline. n = 8 cells from 3 independent 










Figure 10. Quantitative analysis of CM function in response to isoproterenol. 
(A) Representative contraction curves of a single field-stimulated hESC-CM 
treated with the beta-agonist isoproterenol. Changes in Fluo-4, AM calcium 
transient indicator intensity (top panel), percentage cell length (middle panel), and 
contractile force (bottom panel) of the cell over time are shown. (B-G) Fold change 
in calcium transient amplitude (∆F/F0), peak force (PF), maximum shortening 
velocity (-∆L/∆t), maximum relengthening velocity (+∆L/∆t), time to 50% peak 
shortening (TPS50), and time to 90% relengthening (TR90) of cells treated with 
10nM and 100nM isoproterenol compared to baseline. n = 9 cells from 3 
independent experiments. Data are represented as mean ± SE. *P<0.05; **P<0.01; 









Figure 11. Intercell variability of hESC-CMs in response to isoproterenol and 
effect of isoproterenol on adult CMs. (A-F) Intercellular variability in contractile 
characteristics of hESC-CMs at baseline and in response to treatment with 10nM 
and 100nM isoproterenol. Each colored line represents one cell. (G) 
Representative contraction curves of a single isolated field-stimulated adult CM 
before and after treatment with 100nM isoproterenol. (H-M) Fold change in peak 
shortening (ΔL), maximum shortening velocity (-ΔL/Δt), time to 50% peak 
shortening (TPS50), maximum relengthening velocity (+ΔL/Δt), time to 50% 
relengthening (TR50) and time to 90% relengthening (TR90) of adult CMs after 
treatment with 100nM isoproterenol compared to baseline. n= 7 cells from 3 









Figure 12. Rapid evaluation of drug-induced cardiac toxicity in single 
cardiomyocytes. (A) Representative contraction curves of a single spontaneously 
contracting CM at baseline (0nM dofetilide). Changes in FluoVolt action potential 
indicator intensity (top panel), percentage cell length (middle panel), and 
contractile force (bottom panel) of the cell over time are shown. (B-D) 
Representative contraction curves of single CMs treated with 10nM of dofetilide 
showing occurrences of early afterdepolarizations (closed arrows) without 
aftercontractions (closed arrowheads) (B), irregular interbeat-intervals (IBI) and 
peak contraction amplitudes (PA)(C) and absent contractions (open arrowheads) 
with regular action potential (open arrows) in addition to irregular interbeat-
intervals and peak contraction amplitudes (D). (E) The percentage coefficient of 
variation (COV (%)) of the interbeat intervals measured by action potential (AP) 
and BASiC treated with (+) and without (-) dofetilide. (F) The COV (%) of the peak 
contraction amplitude measured by action potential and BASiC treated with (+) and 
without (-) dofetilide. *P<0.05; **P<0.01. n = 10 cells from 3 independent 




CHAPTER THREE: METABOLIC MATURATION OF HUMAN PLURIPOTENT 






Human Pluripotent Stem Cell-Derived Cardiomyocytes (hPSC-CMs) have 
been widely used for cardiac disease modeling86,95,96, drug discovery97,98 and 
cardiac toxicity screenings99-101 in vitro. Unlike primary human CMs which have 
limited availability and are difficult to maintain in culture, hPSC-CMs can be easily 
generated and cultured in vitro with unlimited quantities. They have also been 
shown to exhibit similar electrical activities and contractile capabilities compared 
to primary CMs29,30. However, hPSC-CMs exhibit metabolically and functionally 
immature phenotypes when cultured in traditional culture media46,102,103. They 
mainly utilize glycolysis for energy production in vitro as opposed to the 
predominantly oxidative metabolism observed in normal adult hearts104,105. 
Many promising approaches have been proposed to enhance hPSC-CMs’ 
maturation including biophysical, biochemical and bioelectrical stimulations30. 
While most studies focused on characterizing CMs’ morphological, electrical and 
contractile phenotypes when assessing maturation states, the role of energy 
substrate and metabolic pathway utilizations on CM maturation remains poorly 
understood. Several signaling molecules have been identified as important factors 
in promoting maturation of hPSC-CMs including AMPK/mTORC1 pathway106, 
thyroid hormone107,108 and microRNAs109,110. In a recent publication, Correia et al. 
showed that by depriving glucose and supplementing fatty acids in the culture 
media, hPSC-CMs are metabolically and functionally more mature105. However, 




remains to be elucidated. 
During heart development, a major metabolic switch from glycolytic to 
oxidative energy production occurs shortly after birth45. In the fetal heart, most of 
ATP is produced by glycolytic breakdown of glucose whereas the majority of ATP 
synthesis in the adult heart comes from fatty acid β oxidation in the mitochondria45. 
Since tremendous amount of energy is required constantly for proper heart 
function, it is essential for mature cardiomyocytes to utilize oxidative 
phosphorylation (OXPHOS) as a robust and effective pathway for ATP synthesis. 
Therefore, the metabolic switch to oxidative energy production is a hallmark of 
cardiac metabolic maturation.  
Hypoxia-inducible factor 1-alpha (HIF1α) has been identified as a primary 
transcriptional factor and master regulator of cellular hypoxia responses in multiple 
organ systems in the body111,112. Under physiological conditions, HIF1α is targeted 
by E3 ubiquitin ligase Von Hippel–Lindau tumor suppressor (VHL) and degraded 
rapidly by the ubiquitin protease pathway. A decrease in cellular oxygen levels 
stabilizes HIF1α and causes HIF1α proteins to accumulate in the nucleus113,114. 
Extensive body of literature has established HIF1α as a central regulatory molecule 
in cancer cell metabolism115-117. Cancer cells utilize a high rate of glycolysis to 
synthesize ATP followed by lactic acid fermentation rather than producing energy 
through oxidative pathways in the mitochondria, known as the Warburg effect118. 
By regulating key metabolic enzymes’ expression and activity, HIF1α promotes 




mitochondria115. Okamoto et al. have recently shown that HIF1α reduces cellular 
oxygen consumption and mitochondria electron transport chain activities119. HIF1α 
activation has also been shown to upregulate glycolytic enzymes including lactate 
dehydrogenase A (LDHA), which is required for the conversion of pyruvate to 
lactate120,121 Since LDHA plays a critical role in cancer metabolism, targeting LDHA 
has been proposed as a potential therapeutic strategy for inhibiting tumorigenesis 
and progression122,123. In the heart, HIF1α signaling has been shown to be a key 
pathway for metabolic signaling during cardiac development and maturation in 
vivo124-126. Menendez-Montes et al., recently showed that HIF1α signaling is 
essential in controlling the embryonic metabolic switch from glycolysis to oxidative 
phosphorylation, which is essential for cardiac maturation in vivo126. Given the 
central role of HIF1α in regulating metabolic substrate selection and the abnormal 
glucose utilization in hPSC-CMs, we hypothesized that the HIF1α-LDHA signaling 
pathway plays an essential role in regulating metabolic and functional maturation 
of cultured CMs.  
Accordingly, the aim of this study is to investigate the underlying signaling 
mechanism controlling CMs’ energy substrate selection and metabolic maturation 
of hPSC-CMs. To address this, we investigated the metabolic and physiological 
consequences of culturing hPSC-CMs in three different media compositions: 
glucose media (GLM), glucose media supplemented with fatty acids (GFAM) and 
fatty acids only media deprived of glucose (FAM). Metabolic and functional 




medium promotes glycolytic metabolism, even in the presence of fatty acids 
whereas media containing fatty acids as the only energy source allowed for normal 
physiological metabolic substrate utilization. We then show that HIF1α-LDHA axis 
is aberrantly upregulated in CMs cultured on glucose containing media. Small 
molecule inhibition of the HIF1α-LDHA pathway results in enhanced metabolic and 
functional maturation of hPSC-CMs. Collectively our results highlight the 
importance of controlling the metabolic maturation of stem cell derived CMs in 




MATERIALS AND METHODS 
Human Pluripotent Stem Cell Culture and Differentiation 
The stem cells used in this study include HUES9 (NIH Human Embryonic 
Stem Cell Registry Number 0022, generated by HSCI iPS Core at Harvard 
University), H7 (WA07, NIH Human Embryonic Stem Cell Registry Number 0067, 
generated by WiCell Research Institute) and iPSC (BJ RiPS-D - Healthy Donor 
Control (Male), generated by HSCI iPS Core at Harvard University).  
hPSCs were cultured with Essential 8 Media (Thermo Fisher Scientific, MA) 
in polystyrene plates coated with Matrigel (BD Biosciences) as described 
previously127. hPSCs were passaged using 0.5mM EDTA in PBS. Small molecule 
differentiation of hPSCs into CMs was performed using an established protocol26. 
Spontaneously contracting CMs were dissociated using TrypLE Express Enzyme 
(Thermo Fisher Scientific, MA) at day 20 differentiation and replated onto Matrigel 
coated plates.  
The three media compositions used are as follows: GLM contains RPMI 
Medium with GlutaMAX Supplement (Thermo Fisher Scientific, MA) plus Gem21 
NeuroPlex Serum-Free Supplement (Gemini Bio-Products, CA). GFAM contains 
GLM plus 50 µmol/L of Palmitic Acid (Sigma, MO) and 100 µmol/L Oleic Acid. FAM 
contains RPMI Medium without glucose (Thermo Fisher Scientific, MA) plus 50 
µmol/L of Palmitic Acid (Sigma, MO) and 100 µmol/L Oleic Acid105. CMs were 
cultured in different media compositions with or without small molecule treatments 




Animal Procedures and Hexokinase Activity Assay 
C57BL/6 mouse were used in this study. Hearts from embryonic day 15, 
postnatal day 2 and adult mice were harvested in lysis buffer and homogenized 
using TissueLyser LT (Qiagen, Germany). Mice studies were approved by the 
Subcommittee on Research Animal Care at Massachusetts General Hospital. 
Hexokinase Activity Assays were performed using a commercial assay kit 
(BioVision, CA) according to manufacture suggested protocol.  
Lactate and ATP Measurements 
Cellular and tissue lactate levels were measured using Lactate Assay Kit 
(Sigma, MO). Cellular and tissue ATP levels were measured using CellTiter-Glo 
Luminescent Assay (Promega, WI). Cell numbers were determined by both 
PrestoBlue Cell Viability Reagent (Thermo Fisher Scientific, MA) and counting 
cells using a hemocytometer. 
Seahorse Live-cell Metabolic Assay 
Live-cell metabolic assays were performed with Seahorse XFe96 Analyzer 
(Agilent, CA) according to manufacture protocol. hPSC-CMs were plated in 96-well 
assay plates (Agilent, CA) and cultured with GLM, GFAM and FAM treated with 5 
nmol/L Chetomin (CTM, Sigma, MO), 5 µmol/L GSK 2837808A (GSKA, APEXBIO, 
TX) or controls for 10 days. Sensor cartridges were hydrated with calibration buffer 
(Agilent, CA) a day prior to each assay. Prior to the measurements, cells were 
switched to the Seahorse XF Base Medium (Agilent, CA) with added glucose, fatty 




measurements were made for each assay before adding oligomycin, Carbonyl 
cyanide 4-(trifluoromethoxy)phenylhydrazone (FCCP) and antimycin sequentially 
into the media. All measurements were normalized to cell numbers. 
Mitochondria Staining and FACS Analysis 
MitoTracker Deep Red FM fluorescent dye (Thermo Fisher Scientific, MA) 
was added to hPSC-CMs cultured in GLM, GFAM and FAM treated with CTM, 
GSKA, or controls. Following multiple washes, CMs were dissociated, centrifuged 
and resuspended in FACS buffer (PBS with no calcium or magnesium plus 5% 
FBS and DAPI). CMs were analyzed by BD FACSARIA system (BD Biosciences, 
CA). Fluorescent intensities at the APC far-red channel (Ex/Em ~633nm/660nm) 
were recorded. Gating and intensity profile analysis were performed using FlowJo 
software (FLOWJO, LLC, OR). 
Immunostaining and Sarcomere Length Measurements 
Following multiple washes with cold PBS, cells were fixed for 5 min with 4% 
paraformaldehyde and washed again with cold PBS. Samples were then incubated 
for 2 hours at room temperature with a blocking solution consisting of 5% donkey 
serum and 0.1% Triton-X in PBS. Primary antibodies were diluted in 0.1% Triton-
X, 2% donkey serum in PBS and incubated overnight at 4 ˚C. Following multiple 
washing steps, samples were incubated with secondary antibodies diluted in 0.1% 
Triton-X and 2% donkey serum for 2 hours in room temperature. Samples were 
then washed, incubated with DAPI in PBS for 5 minutes and washed again before 




(EP1215Y, Abcam, Cambridge, UK), anti-sarcomeric alpha actinin (A7811, Sigma, 
MO) and Pierce Cardiac Troponin (MA5-12960 and MAB1874, Thermo Fisher 
Scientific, MA), Myosin regulatory light chain 2, atrial isoform (MLC2a, 311011, 
Synaptic Systems, Germany) and Myosin regulatory light chain 2, 
ventricular/cardiac muscle isoform (MLC-2, 10906-I-AP, Proteintech, IL, USA). 
Secondary antibodies include donkey-anti-mouse and donkey-anti-rabbit 488, 546, 
647 (Thermo Fisher Scientific, MA). Sarcomere lengths were measured using 
ImageJ software. Lengths of five sarcomeres from each cell were measured and 
averaged for each condition. 
siRNA Transfections 
HIF1α and control siRNAs (Sigma, MO) were transfected to CMs using 
Lipofectamine 3000 Reagent (Thermo Fisher Scientific, MA). Complexation 
reaction of RNAs and lipofectamine reagents were performed in Opti-MEM media 
(Thermo Fisher Scientific, MA). After the incubation period, the mixture was added 
to the CMs and experiments were performed after 96 hours. 
Western Blotting and RT-PCR 
Cultured hPSC-CM samples were lysed in RIPA buffer (Boston BioProducts, 
MA) with protease and phosphatase inhibitors (Thermo Fisher Scientific, MA). 
Protein concentration was measured by BCA assay (Thermo Fisher Scientific, MA). 
SDS-PAGE was used to resolve the lysates, which were then transferred onto a 
PVDF membrane (Merck Millipore ltd. MA) and incubated overnight with primary 




secondary HRP-linked antibodies (Cell Signaling Technologies, MA) and then 
treated with SuperSignal™ West Chemiluminescent Substrate (Thermo Fisher 
Scientific, MA). Chemiluminescent images were acquired using ChemiDoc™ 
Imaging Systems (Bio-Rad Laboratories, Inc., CA). The primary antibodies used 
for western blotting include: anti-HIF-1 alpha (Abcam, Cambridge, UK), anti-
GAPDH (Cell Signaling Technologies, MA). Signal intensity was quantified by 
Image Lab software version 5.2.1 (Bio-Rad Laboratories, Inc., CA).  
For qPCR experiments, RNA from hPSC-CMs was extracted using RNeasy 
kit (Qiagen, Germany). Reverse transcriptions were done using iScript kit (Bio-Rad 
Laboratories, Inc., CA). qPCR experiments were performed with HotStart-IT SYBR 
Green kit (Affymetrix, CA) using QuantStudio 3 software (Applied Biosystems, CA).  
Confocal Imaging and Single Cell Functional Studies 
Immunofluorescent stainings were imaged using confocal laser scanning 
microscope Leica TCS SP8 (Leica, Germany). For single cell imaging, 
polydimethylsiloxane (PDMS) plates were prepared according to previously 
established protocol127. hPSC-CMs were plated at single cell density on 5kPA 
PDMS plates with Matrigel coating. Calcium transients were visualized using Fluo-
4 AM calcium indicator (Thermo Fisher Scientific, MA). Videos of CMs’ calcium 
transient and contractions were captured using the 488 and DIC channels, 
respectively, at 50 frames per second.     
Contractile force generation of single hPSC-CMs were quantified using 




captured by high-speed confocal microscopy (50 frames per second). Maximum 
and minimum cell length during contractions as well as cell widths were measured 
using ImageJ. Maximum contractile forces generated during contractions were 
then calculated using previously published customized Matlab code127. 
siRNA Transfections 
The siRNAs used in this study are MISSION esiRNA human HIF1A 
(esiRNA1) and MISSION esiRNA targeting EGFP (esiRNA1) (Sigma, MO). siRNAs 
were transfected to CMs using Lipofectamine 3000 Reagent (Thermo Fisher 
Scientific, MA). Complexation reaction of RNAs and lipofectamine reagents were 
performed in Opti-MEM media (Thermo Fisher Scientific, MA). After the incubation 
period, the mixture was added to the CMs and experiments were performed after 
96 hours.  
Transmission Electron Microscopy (TEM) 
CMs for TEM were fixed with glutaldehyde solution for 2 hours in room 
temperature and washed with cacodylate rinse buffer. Cells were then scraped 
from the plates and centrifuged. Following agarose processing and embedding, 
the samples were then sectioned, and contrast stained for imaging. TEM images 
were acquired at random locations throughout the samples. 
Statistical Analysis 
Statistical analysis was performed using GraphPad Prism software (La Jolla, 
CA). The sample size for each group is shown in the figure legends. Results for 




experiments. Statistical differences of multiple groups were performed using one-





hPSC and CM Characterizations 
 To ensure the quality of the cells and repeatability of our results, we 
replicated some of our experiments in three different hPSCs. The cell culture, 
differentiation and treatment timeline is illustrated in Fig. 13. We observed high 
pluripotency in all three hPSC lines with no obvious difference among them (Fig. 
14). We performed immunofluorescent staining of cardiac troponin T to quantify 
the purity of CMs after 20 days differentiation and purification using both FACS 
analysis and confocal imaging. We found highly pure populations of CMs (>90%) 
following differentiation from all three cell lines (Fig. 15 A-E) and after small 
molecule treatments (Fig. 15 F). We further characterized CMs derived from the 
three cell lines by performing immunofluorescent staining of cardiac troponin T, 
MLC2V and MLC2a. We observed similar expression patterns of these markers 
on CMs derived from all three lines (Fig. 16). 
hPSC-CMs Cultured in GLM and GFAM Lack Metabolic and Functional 
Maturation 
Prior reports have suggested that the mammalian embryonic heart depends 
on glycolysis for ATP production whereas the adult heart switches to primarily 
oxidative phosphorylation to produce energy. To verify these findings and establish 
a baseline control for hPSC-CMs, we followed the changes in glycolysis rates of 
at different stages of heart development and maturation. We measured hexokinase 




and adult mice using colorimetric commercial assay kit. Hexokinase converts 
glucose into glucose-6-phosphate, which is oxidized to form NADH. The resulting 
NADH then reduces a colorless probe into a colorimetric product indicative of the 
hexokinase enzyme activity levels. As expected, we observed significantly higher 
hexokinase activities in immature embryonic and postnatal hearts compared to 
adult hearts (Fig. 17A). We then used the same hexokinase assay to compare the 
glycolysis rates of hPSC-CMs cultured in glucose containing media (GLM, GFAM) 
and media with fatty acids as the only energy source (FAM). hPSC-CMs cultured 
in FAM had significantly lower hexokinase activities compared to CMs cultured in 
GLM and GFAM (Fig. 17B). We also found that hexokinase protein levels are 
similar in GLM, GFAM and FAM (Fig. 17D). Glycolysis results in the conversion of 
glucose into pyruvate, which is subsequently reduced into lactate. To further 
validate that the increase in hexokinase activity is due to an increase in glycolysis, 
we compared the total cellular lactate levels in CMs cultured under different growth 
conditions using a commercial lactate assay kit. In this assay, lactate is oxidized 
into pyruvate generating NADH in the process. NADH generated then reacts with 
a substrate allowing for colorimetric readout, which is proportional to the amount 
of lactate in the samples.  As shown in Figure 17C, CMs cultured in GLM and 
GFAM had significantly higher lactate levels compared to CMs cultured in FAM. 
These results show that hPSC-CMs cultured in the glucose containing media GLM 
and GFAM have a high glycolytic rate that is similar to embryonic and postnatal 




energy source had glycolysis rates that were similar to the adult heart.   
We then assessed rates of oxidative metabolism in hPSC-CMs cultured in 
GLM, GFAM and FAM using the Seahorse Live-cell Metabolic Assay. CMs 
cultured in GLM and GFAM had significantly lower oxygen consumption rates 
(OCR, Fig. 17E) compared to CMs cultured in FAM. We then performed 
mitochondria stress test by sequentially adding oligomycin, FCCP, and antimycin 
to CMs cultured in all three media. CMs cultured in FAM had a significant increase 
in OCR with FCCP treatment compared to CMs cultured in GLM and GFAM (Fig. 
17F). This response indicates a much larger spare capacity for CMs cultured in 
FAM compared to GLM and GFAM. To assess ATP production, we measured CM 
ATP levels using the CellTiter-Glo assay. CMs cultured in GLM and GFAM had 
significantly lower levels of ATP per cell compared to CMs cultured in FAM (Fig. 
17G). These results support our findings that hPSC-CMs cultured in GLM and 
GFAM are metabolically reliant on glycolysis rather than oxidative phosphorylation 
and furthermore that they generate less ATP compared to CMs cultured in FAM. 
Since oxidative phosphorylation is a mitochondrial process, we then 
compared the number of mitochondria among hPSC-CMs cultured in GLM, GFAM 
and FAM using mitotracker deep red staining and quantitative flow cytometry. We 
observed that CMs cultured in GLM and GFAM have significantly lower median 
mitotracker intensities compared to that of FAM (Fig. 18A-B). We also observed a 
higher sarcomere length (Fig. 18C) and peak contractile force generation (Fig. 




results taken together show that CMs cultured in the presence of glucose resemble 
immature embryonic and neonatal cardiomyocytes with respect to their energy 
substrate utilization, active metabolic pathways, and mitochondrial content. In 
contrast, CMs cultured in the presence of fatty acids as the primary energy source 
more closely resemble adult CMs, consistent with previous reports105. 
Aberrant Activation of HIF1α and LDHA Pathway in Cultured CMs 
HIF1α is a central regulator of metabolism and promotes glycolysis at the 
expense of oxidative phosphorylation. To test a potential role for this pathway in 
controlling the observed inappropriate energy substrate selection in glucose 
cultured CMs, we performed immunofluorescent staining of HIF1α in hPSC-CMs 
cultured in GLM, GFAM and FAM. We found that CMs cultured in the presence of 
glucose had high levels of HIF1α in the nucleus and low levels in the cytoplasm. 
This high nuclear to cytoplasmic ratio of HIF1α protein and localizations are 
consistent with the activation of the HIF1α pathway. In contrast, HIF1α was 
primarily localized to the cytoplasm in cells cultured in FAM (Fig. 18). We then 
quantified HIF1α protein expressions using western blot. HIF1α was expressed at 
significantly higher levels in hPSC-CMs cultured in GLM and GFAM compared to 
FAM (Fig. 19A). We then measured the mRNA levels of direct and indirect 
downstream targets of activated HIF1α. Among these transcripts, we found that 
lactate dehydrogenase A (LDHA) has a significantly higher expression in hPSC-
CMs cultured in the presence of glucose (GLM and GFAM) compared to those 




metabolism were not significantly different among the three groups (Fig. 19D-E).  
Activated HIF1α is a transcriptional regulator that has been previously 
shown to act in a positive feedback loop to promote its own transcriptional 
activation128-130. We therefore reasoned that repression of HIF1α activity might 
result in a normalization of its levels at the mRNA and protein level. To test this, 
we then evaluated the effect of HIF1α inhibition by treatment with CTM, a small 
molecule inhibitor of HIF1α’s transcriptional activity (Fig. 19A). Inhibition of HIF1α 
activity normalized its protein expression level. Furthermore, inhibition of HIF1α 
with CTM also significantly reduced LDHA mRNA levels in GLM and GFAM 
cultured CMs (Fig. 19C). These results demonstrate an aberrant activation of 
HIF1α in hPSC-CMs cultured in glucose rich media and raises the possibility that 
repression of this pathway may result in improved metabolic function of CMs 
cultured in vitro. 
 
Inhibition of HIF1α and LDHA Improves CMs’ Metabolic Maturation 
To assess the metabolic impact of inhibiting the HIF1α-LDHA regulatory 
axis, we treated hPSC-CMs cultured in GLM, GFAM and FAM with GSKA (a 
selective and potent LDHA inhibitor) or CTM. We first compared hexokinase 
enzyme activity levels of CMs treated with GSKA, CTM, or carrier control and 
showed that both GSKA and CTM treatments significantly reduced hexokinase 
enzyme activity levels in CMs cultured in GLM and GFAM (Fig. 20A). Similarly, 




then measured the impact of GSKA or CTM treatment on cellular respiration and 
oxidative metabolism using the Seahorse Analyzer and found that CMs treated 
with GSKA had significantly increased OCRs (Fig. 21A) and spare capacities (Fig. 
21B). Similar increases were observed with CTM treatments (Fig. 21C-D). These 
results demonstrate that inhibition of the HIF1α or LDHA inhibits aerobic glycolysis 
and restores normal CM dependence on oxidative phosphorylation. We then 
compared the cellular ATP levels of CMs treated with GSKA or CTM. As shown in 
Figure 20C-D, hESC-CM and hiPSC-CM inhibition of this pathway resulted in an 
increase of cellular ATP production in cells cultured in GLM and GFAM consistent 
with the shift from aerobic glycolysis to oxidative phosphorylation. Collectively, 
these results demonstrate that small molecular inhibition of HIF1α-LDHA promotes 
CMs’ metabolic maturation with reduced glycolysis, increased oxidative 
metabolism and higher cellular ATP productions 
 
Inhibition of HIF1α and LDHA Enhances CMs’ Structural and Functional 
Maturation 
To assess the impact of HIF1α-LDHA inhibition on CMs’ structural 
maturation, we quantified the sarcomere lengths of CMs cultured in GLM, GFAM 
and FAM treated with GSKA, CTM or control. CMs cultured with fatty acids as the 
only energy source (FAM) had significantly longer sarcomere length compared to 
cells cultured in the presence of glucose. Likewise, significant improvements in 




We then investigated the impact of metabolic substrate availability and HIF1α-
LDHA regulation on mitochondrial numbers. As shown in Figure 23B-C, we found 
a significant increase in median mitotracker staining intensities with CTM or GSKA 
treatments in CMs cultured in GFAM. We subsequently examined the effect of 
HIF1α-LDHA inhibition by treatment with GSKA or CTM on structural and 
functional gene expressions. We analyzed several key cardiac functional genes 
and observed a significant increase in the expression levels of gap junction protein 
alpha 1 (GJA1), myosin heavy chain 6 (MYH6), beta-myosin heavy chain (MYH7), 
potassium/sodium hyperpolarization-activated cyclic nucleotide-gated channel 4 
(HCN4), and sodium voltage-gated channel alpha subunit 5 (SCN5) when CMs 
were treated with GSKA or CTM (Fig. 23D). We observed similar improvements 
to CM oxidative metabolism, mitochondrial numbers and sarcomere lengths in H7 
hPSC-CMs (Fig. 24), long-term small molecule treatments (Fig. 25) and HIF1α 
inhibition using siRNA (Fig. 26). 
We then quantified the impact of HIF1α-LDHA inhibition on CMs’ calcium 
transient kinetics and contractility. We show significant increases in peak calcium 
amplitude (Fig. 27A-B), maximum upstroke and decay velocities (Fig. 27C-D), and 
decreases in time to 50% upstroke and decay (Fig. 27E-F) in CMs cultured in 
GFAM and treated with GSKA or CTM compared to FAM. We also observed 
significant increases in peak contractile force generations (Fig. 28A-C), maximum 
shortening velocities (Fig. 28D) and maximum relengthening velocities (Fig. 28E) 




Metabolic pathway utilizations of CMs cultured in FAM, GLM and GFAM treated 
with GSKA or CTM are illustrated in Figure 30. These findings demonstrate that 





hPSC-CMs have been proposed as a promising cell source for drug 
development, human disease modeling, and cardiac toxicity screening in 
vitro86,95,101. Compared to human adult cardiomyocytes, hPSC-CMs are relatively 
immature both morphologically and functionally, lacking normal levels of 
binucleation, well-developed sarcomeres, fast electrical conductivity and oxidative 
metabolism30. To address these limitations, numerous studies have aimed to 
enhance hPSC-CMs’ maturation using genetic, chemical, and biomechanical 
approaches38,80,131. These studies have achieved varying degrees of success in 
terms of improving hPSC-CMs’ morphological, electrical and contractile maturation. 
However, few studies have focused on cellular metabolism as a critical rubric for 
maturation state of CMs. Kim et al. demonstrated the importance of inducing an 
adult-like metabolism in hPSC-CMs to establish an adult-onset disease model in 
vitro104. In this study, we showed that energy production pathway utilization plays 
a major role in regulating maturation state of CMs. 
A number of studies have demonstrated that the embryonic and neonatal 
mammalian heart depends on aerobic glycolysis as the principal energy production 
pathway45. As a result of a postnatal metabolic shift in CM substrate utilization, the 
majority of the energy required for CMs’ contractile function in the adult heart is 
produced through β-oxidation of fatty acids in the mitochondria45. hPSC-CMs 
cultured in vitro primarily utilize glycolytic pathways for energy production46,102. In 




markers to determine the glycolysis rates of hearts during different stages of 
development. Hexokinase is a key enzyme in glycolysis that converts glucose into 
glucose-6-phosphate. Thus, hexokinase enzyme activity levels have been used as 
a surrogate for glycolysis rates132-134. The marked reduction in hexokinase enzyme 
activity in adult relative to neonatal and embryonic hearts is consistent with prior 
reports showing that cardiomyocytes maturation is inversely correlated with 
cellular glycolysis levels45. Similarly, lactate is a byproduct of glycolysis in 
mammalian cells and lactate levels can be used as an indicator for the level of 
glycolysis. As expected, these experiments confirmed prior reports that the 
mammalian heart utilizes mainly glycolysis during embryonic development and 
undergoes a shift to oxidative phosphorylation in the postnatal period. Furthermore, 
our results show that hPSC-CMs cultured under standard glucose culture 
conditions resemble immature CMs’ metabolic profile. Thus these results 
collectively demonstrate that hPSC-CMs cultured in normal cultured conditions 
depend primarily on aerobic glycolysis for energy production and this substrate 
utilization reflects a relative immature embryonic or neonatal metabolic phenotype. 
In accordance with recent reports, we showed that culture media have 
profound impacts on CMs’ metabolism and functions105. CMs deprived of glucose 
and cultured with fatty acids as the primary energy source exhibited significantly 
elevated levels of oxygen consumption, spare capacities and ATP production rates 
compared to CMs cultured in the presence of glucose. CMs cultured in the 




contractile forces. These findings suggest that culturing hPSC-CMs in traditional 
glucose rich media results in a less advanced development and maturation stage 
compared to culturing CMs with fatty acids as the primary energy source. In the 
native heart, although both glucose and fatty acids are available as energy sources, 
adult CMs utilizes mostly the fatty acids for energy production. In contrast, we 
demonstrate that hPSC-CMs cultured in the presence of both glucose and fatty 
acids preferentially utilized glucose as the principle energy source. We show that 
this difference between in vivo and in vitro CMs’ energy substrate utilization plays 
a critical role in determining myocardial metabolic and functional maturation. 
HIF1α has been identified as a master transcriptional regulator of cellular 
hypoxia responses and metabolism111,121. HIF1α expression is crucial for early 
fetal cardiac development135,136. Recent studies have further suggested that 
activation of the HIF1α pathway is required for the maintenance of a myocardial 
proliferative state during early embryonic development126. We therefore 
hypothesized that aberrant activation of this central signaling pathway may be 
responsible for the persistence of an immature metabolic phenotype in hPSC-CMs.  
Activated HIF1α is localized to the nucleus whereas inactive HIF1α remains in the 
cytoplasm where it is rapidly turned over111,113,114. We examined the levels of 
HIF1α activity under different conditions and demonstrated that HIF1α was 
aberrantly activated in hPSC-CMs cultured in the presence of glucose but was 
inactivated when cells were grown with fatty acids as the only significant carbon 




CMs cultured in the presence of glucose and treated with HIF1α transcriptional 
inhibitor, consistent with prior reports that a positive feedback loop coordinates the 
activity HIF1α protein levels with its transcriptional expression128-130. Since cultured 
CMs experience normal oxygen tension in vitro, we postulate that HIF1α 
expression is stabilized due to oxygen independent signaling molecules and 
pathways.  
LDHA is a key target of HIF1α. Its expression is required for the conversion 
of pyruvate to lactate and the restoration of the cellular NAD+ storage required for 
glycolysis. We show that LDHA is significantly upregulated in hPSC-CMs cultured 
in the presence of glucose, consistent with the dependence of these cells on 
glycolytic pathways for energy production. Inhibition of HIF1α activity with CTM 
resulted in reduced LDHA gene expression, confirming that LDHA is a downstream 
target of HIF1α in hPSC-CMs. Likewise, small molecule inhibition of LDHA activity 
suppresses aerobic glycolysis and facilitates oxidative phosphorylation in hPSC-
CMs.   
The expression and activity of HIF1α in hPSC-CMs cultured in the presence 
of glucose is similar to its reported expression during early fetal development. 
Moreover, deletion of VHL during midgestation stage of cardiac development has 
been shown to stabilize HIF1α proteins and prevent metabolic shift from glycolytic 
to oxidative pathway resulting in impaired cardiac maturation and function126.  
Aerobic glycolysis has been previously shown to be activated in oncogenesis and 




treating cancer115,117,123. By inhibiting HIF1α-LDHA signaling pathway, cancer cells 
showed decreasing glycolysis and lactate fermentation rates while reactivating 
metabolic functions122,123. Here, we propose to improve cultured hPSC-CMs’ 
metabolic and functional maturation by shifting its metabolism using small 
molecule HIF1α-LDHA inhibitors. Indeed, increases in OCR, mitochondria spare 
capacities and ATP productions as well as decreases in cellular hexokinase 
activity and lactate levels were observed in hPSC-CMs cultured in GLM and GFAM 
with inhibition of HIF1α/LDHA by CTM/GSKA. It is unclear whether this shift 
resulted in an improved breakdown of pyruvate into acetyl-CoA or an increased 
fatty acids uptake in CMs cultured in GFAM.  
We also showed that shifting CM metabolism to a more oxidative pathway 
positively impacted cellular maturation and contractile function. Improvements in 
sarcomere lengths, mitochondria number, functional gene expressions, calcium 
transient kinetics and contractile force generation were observed in hPSC-CMs 
cultured in in the presence of glucose when the HIF1α/LDHA axis was inhibited 
with CTM or GSKA. Furthermore, peak contractile force generated by single 
hPSC-CMs treated with CTM/GSKA reached similar levels of adult murine CMs 
reported in the literature137,138. These results indicate that inhibiting HIF1α-LDHA 
signaling is an effective strategy for improving hPSC-CMs’ metabolic and 
functional maturation. 
The findings of this study highlight the importance of bioenergetics and 




cell derived CMs. Aberrant activation of the HIF1α/LDHA signaling pathway lead 
to a metabolic shift toward aerobic glycolysis resulting in a decreased number of 
mitochondria, lower ATP cellular levels, impaired calcium handling, and diminished 
contractility. Correcting hPSC-CMs’ metabolic pathway selection and ensuring 
proper mitochondria function are critical steps towards a better representation of 
adult human cardiac physiology and a more appropriate model to study disease 
mechanisms in vitro. Inhibiting signaling to shift CM metabolism towards a more 
oxidative pathway may be a viable option for a developing more clinically relevant 
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Figure 14. Characterization of stem cell lines used in the study. A) Representative 
images of stem cells from 3 cell lines used in this study, HUES9 ESC, H7 ESC and 
iPSC, B) Relative mRNA levels of pluripotency markers in HUES9 ESC, H7 ESC and 









Figure 15. Quantification of CM purity after differentiation. FACS 
quantifications of TnT
+
 cells differentiated from A) iPSC, B) HUES9, C) H7 lines, 
D) Negative control for FACS. E) Percentage of TnT
+
 cells from FACS 
quantification, F) Quantification (left) and a representative image (right) of cardiac 
Troponin positive cells in hPSC-CMs cultured in GLM, GFAM and FAM treated with 








Figure 16. Immunofluorescence characterization of hPSC-CMs from 3 cell 
lines. Immunofluorescent stainings of cardiac troponin T (green), myosin Light 
Chain 2v (red) and 2a (magenta) together with DAPi labeling DNA in CMs derived 










Figure 17. hPSC-CMs cultured in glucose media lack metabolic maturity. A) 
Relative hexokinase enzyme activity in embryonic, neonatal and adult hearts, B) 
Relative hexokinase enzyme activity in hPSC-CMs cultured in GLM, GFAM and 
FAM, C)  Lactate measurements of hPSC-CMs cultured in GLM, GFAM and FAM, 
D) Western blot (left) and quantifications (right) of hexokinase protein expressions 
in hPSC-CMs cultured in GLM, GFAM and FAM, E) Baseline OCR measurements 
of hPSC-CMs cultured in GLM, GFAM and FAM normalized to cell number, F) 
Mitochondria respiration rates of hPSC-CMs cultured in GLM, GFAM and FAM 
normalized to cell number, G) ATP per cell of hPSC-CMs cultured in GLM, GFAM 









Figure 18. hPSC-CMs cultured in glucose media lack structural and 
functional maturity. A) Histogram of hPSC-CMs cultured in GLM, GFAM and FAM 
with mitotracker staining analyzed by FACS with a representative mitotracker 
staining; 10,000 events recorded per group, B) Mean mitotracker staining 
intensities of hPSC-CMs cultured in GLM, GFAM and FAM, C) Sarcomere lengths 
measurements of hPSC-CMs cultured in GLM, GFAM and FAM (n=19 cells) with 
a representative α-actinin staining, green and orange lines represent hPSC-CMs’ 
and adult CMs’ sarcomere lengths reported in the literature, respectively, D) 
Contractile force generated by single hPSC-CMs cultured in GLM, GFAM and FAM 








Figure 19. Aberrant expression of HIF1α in hPSC-CMs cultured in glucose 
media. Immunofluorescent staining of DAPi (blue), HIF1α (green), and α-Actinin 









Figure 20. Aberrant activation of HIF1α-LDHA pathway in hPSC-CMs cultured 
in glucose media. A) Western blot (left) and quantifications (right) of HIF1α 
protein expressions in hPSC-CMs cultured in GLM, GFAM and FAM treated with 
CTM, B) mRNA levels of LDHA and LDHB in hPSC-CMs cultured in GLM, GFAM 
and FAM, C) mRNA levels of LDHA in hPSC-CMs cultured in GLM, GFAM and 
FAM treated with CTM. D) mRNA levels of select transcripts involved in HIF1α 
signaling pathways, E) RNA levels of select transcripts in CM glycolytic and 
oxidative metabolism. No statistical significance were found among GLM, GFAM 










Figure 21. Inhibition of HIF1α and LDHA improves hPSC-CMs metabolic 
maturation. A) Relative hexokinase enzyme activity of hPSC-CMs cultured in 
GLM, GFAM and FAM treated with CTM or GSKA, B) Normalized lactate 
measurements of hPSC-CMs cultured in GLM, GFAM and FAM treated with CTM 
or GSKA, C) Normalized ATP measurements of HUES9 hPSC-CMs cultured in 
GLM, GFAM and FAM treated with CTM or GSKA, D) Normalized ATP 
measurements of hiPSC-CMs cultured in GLM, GFAM and FAM treated with CTM 









Figure 22. Inhibition of HIF1α and LDHA improves hPSC-CMs metabolic 
maturation.  A) Baseline OCR measurements of hPSC-CMs cultured in GLM, 
GFAM and FAM treated with GSKA normalized to cell number, B) Mitochondria 
respiration rates of hPSC-CMs cultured in GLM, GFAM and FAM treated with 
GSKA normalized to cell number, C) Baseline OCR measurements of hPSC-CMs 
cultured in GLM, GFAM and FAM treated with CTM normalized to cell number, D) 
Mitochondria respiration rates of hPSC-CMs cultured in GLM, GFAM and FAM 










Figure 23. Inhibition of HIF1α and LDHA improves hPSC-CMs structural 
maturation. A) Sarcomere lengths measurements of hPSC-CMs cultured in GLM, 
GFAM and FAM treated with CTM or GSKA, green and orange lines represent 
hPSC-CMs’ and adult CMs’ sarcomere lengths reported in the literature, 
respectively; (n=17-53 cells per group), B) Numbers of mitochondria per (100nm)2 
for each cell measured by transmission electron microscopy in hPSC-CMs cultured 
in control GFAM or GFAM+CTM, C) Histogram (left) and quantification (right) of 
hPSC-CMs cultured in GLM, GFAM and FAM treated with CTM or GSKA with 
mitotracker staining (10,000 events recorded per group), D) mRNA levels of 
selected transcripts involved in CM function and maturation in hPSC-CMs cultured 








Figure 24. Inhibition of HIF1α and LDHA improves hPSC-CMs metabolic and 
structural maturation. A) Relative hexokinase enzyme activity, B) relative ATP 
per cell, C) quantification of cell size, D) sarcomere lengths, E) ratio of 
mitochondrial DNA to genomic DNA, and F) quantification of median mitotracker 
staining intensities of H7 hPSC-CMs cultured in GFAM treated with CTM, GSKA 








Figure 25. Inhibition of HIF1α and LDHA improves hPSC-CMs long-term 
metabolic and structural maturation. A) Ratio of mitochondrial DNA to genomic 
DNA, B) quantification of median mitotracker staining intensities, C) quantification 
of cell size, D) sarcomere lengths, and E) relative ATP per cell of hiPSC-CMs 








Figure 26. siRNA knockout of HIF1α Improves hiPSC-CM maturation similar 
to HIF1α small molecule inhibition. A) Relative mRNA levels of HIF1α and LDHA 
of hiPSC-CMs cultured in GFAM transfected with HIF1α siRNA compared to 
control siRNA after 96 hours, B) Relative hexokinase activities, C) ratio of 
mitochondrial DNA to genomic DNA CMs, D) normalized cellular ATP levels, and 
E) fractional shortenings of hiPSC-CMs cultured in GFAM treated with HIF1α 








Figure 27. Inhibition of HIF1α and LDHA improves hPSC-CMs calcium 
handling. A) Representative calcium transient, B) maximum calcium transient 
amplitude, C) maximum calcium transient upstroke velocities, D) maximum 
calcium transient decay velocities, E) time to 50% upstroke calcium transient 
amplitude, and F) time to 50% decay calcium transient amplitude of hPSC-CMs 
cultured in GFAM, GFAM treated with CTM or GSKA and FAM (n=30-50 cells per 















































































































































































































































































Figure 28. Inhibition of HIF1α and LDHA improves hPSC-CMs functional 
maturation. Peak contractile force generated by HUES9 (A) and H7 (B) hESC-
CMs cultured in GLM, GFAM and FAM treated with CTM or GSKA, C) Peak 
contractile forces, D) maximum shortening velocities, and E) maximum 
relengthening velocities of hiPSC-CMs cultured in GFAM, GFAM treated with CTM 



























Figure 29. Representative transmission electron microscopy images. hiPSC-
CMs cultured in GFAM treated with CTM and control are shown. Z = Z disk, M = 









Figure 30. hPSC-CMs metabolic pathway utilization in different media. hPSC-
CMs cultured in FAM (top), GLM/GFAM (middle) and GLM/GFAM plus 




Table 1. List of primers used for qPCR. 
Sirt1 TGTGTCATAGGTTAGGTGGTGA AGCCAATTCTTTTTGTGTTCGTG 
Sirt3 CCCCAAGCCCTTTTTCACTTT CGACACTCTCTCAAGCCCA 
Sirt6 GATGTCGGTGAATTACGCGG TGGAACACCACACTGGAAGAC 
LDHA ATGGCAACTCTAAAGGATCAGC CCAACCCCAACAACTGTAATCT 
LDHB TGGTATGGCGTGTGCTATCAG TTGGCGGTCACAGAATAATCTTT 
PDK1 GAGAGCCACTATGGAACACCA GGAGGTCTCAACACGAGGT 
HK2 TGCCACCAGACTAAACTAGACG CCCGTGCCCACAATGAGAC 
ENO1 GCCGTGAACGAGAAGTCCTG ACGCCTGAAGAGACTCGGT 
VEGFA AGGGCAGAATCATCACGAAGT AGGGTCTCGATTGGATGGCA 
SDHB ACAAGGCTGGAGACAAACCT CCTTCGGGTGCAAGCTAGAG 
SDHA ACTGTTGCAGCACAGCTAGAA GCTCTGTCCACCAAATGCAC 
CA9 GGATCTACCTACTGTTGAGGCT CATAGCGCCAATGACTCTGGT 
DEC1 ATGACAATGAATGTTCTGGAGGC CATCATGTGTAACACGGCAAGA 
PKM ATGTCGAAGCCCCATAGTGAA TGGGTGGTGAATCAATGTCCA 
PKM1 GGCTGAAGGCAGTGATGTGG GAGGATAGTCCCCTTTGGCT 
PKM2 AAGAACTTGTGCGAGCCTCA GACGAGCTGTCTGGGGATTC 
FoxO1 TGATAACTGGAGTACATTTCGCC CGGTCATAATGGGTGAGAGTCT 
FoxO3 ACGGCTGACTGATATGGCAG CGTGATGTTATCCAGCAGGTC 
PGC1a AACAGCAAAAGCCACAAAGACG GGGGTCAGAGGAAGAGATAAAGTTG 
PARP1 TTCAACAAGCAGCAAGTGCC CCTTTGGGGTTACCCACTCC 
PPARA TTCGCAATCCATCGGCGAG CCACAGGATAAGTCACCGAGG 




FGFR1 CCCGTAGCTCCATATTGGACA TTTGCCATTTTTCAACCAGCG 
FOXM1 CGTCGGCCACTGATTCTCAAA GGCAGGGGATCTCTTAGGTTC 
HSF1 GCACATTCCATGCCCAAGTAT GGCCTCTCGTCTATGCTCC 
EGLN1 TCGCAACCCTCATGAAGTACA TAGCTCGTGCTCTCTCATCTG 
NANOG AGATGCCTCACACGGAGACT TTGGGACTGGTGGAAGAATC 
OCT4 AAAGCGAACCAGTATCGAGAAC GCCGGTTACAGAACCACACT 
SOX2 GCCGAGTGGAAACTTTTGTCG GGCAGCGTGTACTTATCCTTCT 
CYTB TCTCCGATCCGTCCCTAACA GTGATTGGCTTAGTGGGCGA 







CHAPTER FOUR: IN VITRO MODELING OF CARDIAC ISCHEMIA 








  Myocardial hypoxia arises from a failure of the oxygen supply of the heart 
to meet its oxygen consumption. This typically occurs due to an acute or chronic 
decrease in the blood flow to the heart. Clinically, this may be due to coronary 
artery disease of the large epicardial vessels, microvascular disease of the small 
intra-myocardial vessels, or even myocardial hypertrophy that results in diffuse 
subendocardial ischemia.139-141 Although tissue hypoxia ultimately results in 
abnormalities in contraction and force generation of the heart, diastolic 
abnormalities are typically observed prior to any measureable change in systolic 
function.142-144 Indeed, despite the long standing focus on systolic abnormalities 
resulting in HF, recent studies have demonstrated that at least half of the patients 
with HF have diastolic dysfunction as the primary cause of the failure and chronic 
ischemia likely plays an important role in the pathogenesis of at least some of 
these cases.145-147 Oxygen is required for normal ATP synthesis under aerobic 
cellular respiration conditions through the oxidative phosphorylation pathway. In 
turn, ATP plays at least two critical roles in mediating the normal contraction and 
relaxation cycle of CMs.  First, ATP is required by the actin/myosin ATPase to 
supply energy for the cross-bridge cycling. ATP binding to the myosin head domain 
induces a conformational change that reduces its affinity for actin and causes the 
myosin head to release the actin filament. Thus, ATP reduction can result in 
relaxation abnormalities by reducing the rate of actin/myosin release. In addition, 




calcium back into the sarcoplasmic reticulum after a contractile cycle. A reduction 
in this ATP-dependent Ca2+ reuptake can also result in delayed relaxation. 
Therefore, ATP hydrolysis is required for both actin/myosin motor and the 
SERCA2a pump. Failure in either step could result in delayed or abnormal 
relaxation of myocardial cells. Which of these two potential mechanisms is 
primarily responsible for the observed relaxation delay in conditions of ATP 
reduction (e.g. during tissue hypoxia) remains an unresolved question however. 
This is an important point since elucidating the precise mechanism of hypoxia-
induced diastolic dysfunction will be key to identify novel treatment strategies. 
Our long-term goal is to the apply knowledge gained from this study toward the 
identification of novel cellular targets for treatment of diastolic dysfunction and 
diastolic hear failure. Therefore, it is critical to perform these studies in human CMs 
since there are important differences between human and rodent cells. Herein we 
propose to develop robust in vitro cellular assays that concurrently and 
quantitatively assess contraction kinetics, calcium transient kinetics and cross-
bridge cycling in single hPSC-CMs. These assays will allow us to probe the 
interplay between different pathophysiologic mechanisms that result in relaxation 
abnormalities during ATP reduction and hypoxic conditions. We believe that this 
study will help us gain new insights into the interactions between cellular pathways 
that lead to cardiac diastolic dysfunction. This knowledge will reveal important 
therapeutic targets for future drug discovery and development that treat diastolic 




 During acute ischemia, cardiac injury occurs in minutes to hours in vivo but 
in hours to days in vitro. This difference in response to ischemia is compounded 
by differences in cardiomyocytes’ (CMs) metabolism and substrate utilization 
under standard in vitro growth conditions. An important challenge in modeling 
ischemia has been to faithfully recapitulate the in vivo cellular response to hypoxic 
stress. To address this limitation, we have performed comprehensive phenotypic 
characterization of myocardial metabolism and contractile functions in vitro during 






MATERIALS AND METHODS 
Live Cell Imaging with Hypoxia and Reperfusion Treatments 
Live cell imaging, both hypoxia and normoxia, were performed using Leica 
SP8 confocal microscope with a stage top chamber (Okolab, CA). Temperature, 
gas and humidity were properly controlled and maintained throughout the 
experiments. For hypoxia experiments, nitrogen was mixed with room air to create 
different oxygen levels. The mixed gas was then humidified and pumped to the 
cells in the stage top chamber. For short term hypoxia experiments, the culture 
media were infused with appropriate hypoxia air mixture 30 minutes prior to the 
experiments.  
Cell Viability and Apoptosis Assays 
Cell viabilities were assayed using LIVE/DEAD™ Viability/Cytotoxicity Kit, 
for mammalian cells (Thermo Fisher Scientific, MA). Following the treatments, 
CMs were incubated with media containing 1µM of Calcein AM and 1µM of 
Ethidium homodimer-1 for 15 minutes. The cells were then washed and imaged in 
Tyrode’s Solution (Sigma, MO). Multiple random field of views were selected and 
imaged for each condition. The number of live cells (488nm) and dead cells 
(546nm) were counted. Cell viability is calculated by: 
 %𝐿𝑖𝑣𝑖𝑛𝑔 𝐶𝑒𝑙𝑙𝑠 = 100% ×  
#  
(#    #  )
 
Cellular apoptosis were assessed using TUNEL In Situ cell Death Detection 
Kit, TMR red (Sigma, MO). Samples were fixed with 4% Paraformaldehyde in PBS, 




permeabilization buffer consists of 0.1% TritonX-100 in 0.1% sodium citrate for for 
2 minutes on ice. After additional washing steps, the samples were incubated in 
TUNEL reaction mixture consists of 90% label solution and 10% enzyme solution 
in a humidified plate for 60 min at +37°C in the dark. Lastly, DAPI was added to 
the samples for visualization of nuclei. Multiple random field of views were selected 
and imaged for each condition. Cellular apoptosis was calculated by: 










Hypoxic Reduction of Cellular ATP is Dependent of Energy Substrate  
We investigated the impact of hypoxia on CM function. We observed strong 
dependencies of CMs’ hypoxic responses on energy substrates available. In 
glucose containing media GLM (Fig. 31A) and GFAM (Fig. 31B), ATP levels 
remained unchanged when CMs were exposed to hypoxia. In contrast, significant 
decreases in CM ATP levels were observed when cultured in FAM and treated 
with hypoxia (Fig. 31C). Similar results were observed in NRVMs cultured in GLM 
(Fig. 31D) and FAM (Fig. 31E) when exposed to 5% hypoxia for 2 hours. We then 
tested the effect of overnight hypoxia treatments. After 24 hours of low oxygen 
treatments, hPSC-CMs cultured in glucose media (Fig. 31F) showed no changes 
in ATP levels, while hPSC-CMs cultured in FAM without glucose (Fig. 31G) had 
significant decrease in ATP levels. To verify that the observed energy substrate 
dependency of CMs’ hypoxic responses were due to the presence of glucose, we 
removed glucose from GLM and GFAM cultured CMs and replaced the media with 
FAM for 24 hours prior to the treatments. Significant decreases in cellular ATP 
levels were observed in these groups after 2 hours of hypoxia treatments, similar 
to CMs in FAM (Fig. 31H-J).  
 
Hypoxic Reduction of CM Contractility is Dependent of Energy Substrates  
We then characterized changes in hPSC-CMs’ contractile functions during 




we found that CMs in media containing glucose did not change fractional 
shortening (FS) when stimulated with hypoxic, while CMs cultured in media without 
glucose had significant decreases in FS after 2 and 4 hours of 2% hypoxia (Fig. 
32). CMs cultured in FAM without glucose showed dose and time dependent 
responses to hypoxia including changes in fractional shortenings, shortening 
velocities and relengthening velocities (Fig. 32-36). We also performed in vitro 
chemical hypoxia using oligomycin to directly inhibit ATP production in the 
mitochondria. Consistent with the results from the hypoxia experiments, CMs 
cultured in GLM and GFAM did not respond to oligomycin treatments while CMs 
cultured in FAM without glucose showed dose and time dependent decreases in 
cellular ATP levels (Fig. 37A) and contractile functions (Fig. 37B-E). 
 
Coverslip Ischemia Reperfusion Injury Results in Cell Death and Apoptosis  
We adopted an established coverslip IR model to investigate the impact of 
perfusion limitation on hPSC-CMs in vitro (Fig. 38A). Contracting CMs were plated 
onto either PDMS or none-coated polystyrene culture plates. Consistent from 
findings described in chapter 2, CMs cultured on PDMS plates were able to shorten 
in lengths, more metabolically active, and thus generated more ATP per cell (Fig. 
38B). The increased metabolic and contractile activity of CMs cultured on PDMS 
plates resulted in their increased sensitivities to coverslip ischemic injuries (Fig. 
38C). CMs on PDMS showed marked decrease in ATP levels with higher amounts 




Significant increases in the percentage of TUNEL positive apoptotic cells after 
coverslip ischemia-reperfusion (Fig. 38D, 39) injuries in CMs cultured on PDMS 
and polystyrene. No significant differences were observed between percentage of 
apoptotic CMs cultured on PDMS versus polystyrene. 
We then quantified the percentage of living cells after coverslip IR injury. 
We found that significant cell deaths had occurred after 2 hours of coverslip 
ischemia and the injuries exacerbated following 2 hours of reperfusion (Fig. 40A, 
41). Cell deaths were not dependent on addition of glucose in the media in 
coverslip IR model (Fig. 40B). To assess the impact of coverslip IR on cellular 
apoptosis, we quantified the percentage of TUNEL positive CMs after the injuries. 
Significant increases in apoptotic cells were found after 2 hours of ischemia and 
further damages were found following 2 hours of reperfusion (Fig. 40C). Cellular 
apoptosis was independent from the addition of glucose in the media in coverslip 
IR model (Fig. 40C). We then investigated whether decreases in oxygen or pH 
alone significantly contributes to cellular apoptosis. To isolate the role of oxygen, 
we cultured CMs in media without glucose and exposed them to 2% hypoxia for 4 
hours and subsequent reoxygenations. Significant increases in percentages of 
apoptotic cells were observed only after 2, 4 or 24 hours of reoxygenation, but not 





During an MI, a severe decrease in oxygen level impairs the heart’s ability 
to generate ATP through OXPHOS. The heart quickly switches metabolism from 
OXPHOS to glycolysis to compensate for the loss of ATP. However, due to the 
reduced efficiency on ATP production and limited glucose supply, ATP of the heart 
continue to decrease. Consequently, cardiac calcium handling and contractility are 
severely impaired. During this process, significant increases in lactate production 
and subsequent decreases in cellular pH occur. Dramatic decreases in oxygen, 
ATP production and pH levels as well as lactate accumulation have been identified 
as the major reasons responsible for ischemic cell death and apoptosis. During the 
reperfusion step, further cellular damages occur potentially due to the flux of 
oxygen, increases in ROS production and rapid pH normalization. Although 
several studies have investigated the role of these changes on cardiomyocytes, 
the precise mechanism of cardiac cell death and apoptosis during ischemia and 
reperfusion injuries have yet to be elucidated. It is also unclear whether changes 
to any single cellular characteristics or a combination of factors is responsible for 
cardiomyocyte death. 
With recent advances in human stem cell culture and differentiation, hPSC-
CMs have been shown to be a powerful tool for studying pathophysiology and 
modeling cardiac diseases in vitro. One major advantage of using hPSC-CMs in 
vitro is the ability to isolate the cell autonomous effect of specific disease conditions 




to develop highly targeted drugs and therapeutics for these diseases. However, 
compared to the traditionally simple cell culture conditions, the biochemical and 
biophysical environment in the heart is significantly more complex.  Thus, it is 
crucial to develop physiologically relevant in vitro models of cardiac diseases that 
are capable accurate depicting cardiac biology and stress responses. 
We first observed that hPSC-CMs’ responses to hypoxic insults are highly 
dependent on the presence of glucose. Hypoxia alone did not produce any adverse 
effects in CMs when glucose is present. These findings are consistent with results 
from Chapter 3, confirming the ability for hPSC-CMs to utilize mainly glycolysis for 
energy production. Thus, it is not physiologically appropriate to study hypoxic 
effects in CMs cultured in glucose rich media. By removing glucose from the 
culture media, we observed physiological responses of CMs to hypoxia in a time 
and dose dependent manner.  
Next, to mimic cardiac biology in vitro using hPSC-CMs, it’s important to 
consider the biochemical and biophysical environment of cultured cells. Substrate 
stiffness has been shown to play a significant role in cellular functions. We 
compared culturing CMs on a more physiological stiffness (kPa) to traditional 
tissue culture plates (GPa). We demonstrated that cellular energetics play an 
important role in hPSC-CMs’ stress responses in vitro. Unlike the traditional stiff 
PS surfaces, soft PDMS substrates with physiological stiffness allow CMs to 
shorten in lengths. Thus, culturing hPSC-CMs on PDMS mimics the mechanical 




PDMS substrates had higher ATP per cell and were more sensitive to coverslip 
ischemia reperfusion injuries. Significant increases in apoptotic cells were 
observed in hPSC-CMs treated with coverslip ischemia and ischemia plus 
reperfusion.  
Although cellular ATP changes during ischemia and IR injuries are 
dependent on substrate stiffness and the presence of glucose, cell death and 
apoptosis, interestingly, are independent from them. Culturing hPSC-CMs on soft 
PDMS substrates resulted in similar percentage of apoptotic cells during ischemia 
and IR injuries compared to hPSC-CMs cultured on PS. Likewise, hPSC-CMs 
cultured in glucose rich media had the same amount of cell death and apoptosis 
as hPSC-CMs cultured in glucose deprived media. We also observed significantly 
higher apoptotic rates of hPSC-CMs during reperfusion after exposing them to 
longer ischemia durations (4 hours). These findings suggest that in vitro IR injury 
in hPSC-CMs is a dynamic process highly dependent on exposure time and 



















































































































































































































Figure 31. Hypoxia reduces cellular ATP levels only in media lacking glucose.  
Relative ATP levels of hPSC-CMs cultured in GLM (A), GFAM (B), and FAM (C) 
exposed to hypoxia, Relative ATP levels of NRVMs cultured in GLM (D) and FAM 
(E) exposed to hypoxia for 2 hours, Relative ATP levels of hPSC-CMs cultured in 
GLM (F) and FAM (G) exposed to hypoxia for 24 hours, Relative ATP levels of 
hPSC-CMs cultured in GLM (H), GFAM (I) and FAM (G) switched to FAM for 24 
hours and then exposed to hypoxia for 2 hours. Error bars represent SEM and 










Figure 32. hPSC-CMs respond to hypoxia only in culture media without 
glucose. A) Fractional shortening of CMs cultured in GLM, GFAM and FAM 
exposed to 2% hypoxia or 21% control conditions, B) Fractional shortening of CMs 
cultured in FAM exposed to different hypoxic conditions for 2 and 4 hours, C) 
Shortening velocities of CMs cultured in FAM exposed to different hypoxic 
conditions for 2 and 4 hours, D) Relengthening velocities of CMs cultured in FAM 
exposed to different hypoxic conditions for 2 and 4 hours, and E) Time to 90% 
relaxation of CMs cultured in FAM exposed to different hypoxic conditions for 2 
and 4 hours. N=9-32 cells per group. Error bars represent SEM and statistically 











































































































































Figure 33. Functional characterization of hPSC-CM cultured in FAM exposed 
to 2% hypoxia for 2 and 4 hours. A) Beats per minute, B) Fractional shortening, 
C) Shortening velocities, D) Relengthening velocities, and E) Time to 90% 
relaxation. N=15 cells. Error bars represent SEM and statistically significance was 














































































































































Figure 34. Functional characterization of hPSC-CM cultured in FAM exposed 
to 5% hypoxia for 2 and 4 hours. A) Beats per minute, B) Fractional shortening, 
C) Shortening velocities, D) Relengthening velocities, and E) Time to 90% 
relaxation. N=10 cells. Error bars represent SEM and statistically significance was 












































































































































Figure 35. Functional characterization of hPSC-CM cultured in FAM exposed 
to 10% hypoxia for 2 and 4 hours. A) Beats per minute, B) Fractional shortening, 
C) Shortening velocities, D) Relengthening velocities, and E) Time to 90% 
relaxation. N=10 cells. Error bars represent SEM and statistically significance was 












































































































































Figure 36. Functional characterization of hPSC-CM cultured in FAM in 
control condition for 2 and 4 hours. A) Beats per minute, B) Fractional 
shortening, C) Shortening velocities, D) Relengthening velocities, and E) Time to 
90% relaxation. N=9 cells. Error bars represent SEM and statistically significance 
























































































































































Figure 37. hPSC-CMs respond to ATP inhibition by oligomycin only in culture 
media without glucose. A) Cellular ATP levels decrease with oligomycin 
treatment in a dose dependent manner only in CMs cultured in media without 
glucose, B) Fractional shortening of CMs cultured in GLM, GFAM and FAM treated 
with oligomycin, C) Shortening velocities of CMs cultured in FAM treated with 
oligomycin, D) Relengthening velocities of CMs cultured in FAM treated with 
oligomycin, E) Time to 90% relaxation of CMs cultured in FAM treated with 
oligomycin. Error bars represent SEM and statistically significance was calculated 









Figure 38. Modeling Ischemia Reperfusion Injuries in vitro with coverslip 
method. A) Schematic drawing of the coverslip ischemia-reperfusion model, B) 
Relative ATP per cell of hPSC-CMs cultured on PS versus PDMS, C) Relative ATP 
levels of hPSC-CMs cultured on PS and PDMS treated with coverslip ischemia for 
2 hours with different volumes of media, D) Percentage of TUNEL positive hPSC-
CMs cultured on PS and PDMS treated with CS ischemia (2hrs) and reperfusion 

















Figure 39. TUNEL stainings for cellular apoptosis in hPSC-CMs treated with 
coverslip IR. Control (A) and coverslip IR (B). Blue is DAPI staining for DNA and 
red is Terminal deoxynucleotidyl transferase (TdT) dUTP Nick-End Labeling 









Figure 40. Coverslip ischemia-reperfusion injury induces cell death and 
apoptosis.  A) Percentage of living cells cultured on PDMS in media with or 
without glucose exposed to ischemia only or ischemia reperfusion, B) Percentage 
of TUNEL positive hPSC-CMs cultured on PS and PDMS treated with CS ischemia 
for 2 hours and CS ischemia for 2 hours plus reperfusion for 2 hours, C) 
Percentage of TUNEL positive cells cultured on PDMS in media without glucose 
exposed to 4 hours hypoxia and different durations of reoxygenation.  Error bars 










Figure 41. LIVE/DEAD Cell Viability Assays for hPSC-CMs treated with 
coverslip IR. Control (A), 0.5 hour of coverslip ischemia (B), 2 hours of coverslip 
ischemia (C) and 2 hours of coverslip ischemia plus 2 hours of reperfusion (D). 
Green is calcein staining for live cells and red is Ethidium homodimer-1 staining 





CHAPTER FIVE: CONCLUSIONS AND PERSPECTIVES 
Cardiovascular disease such as advanced stage heart failure remains a 
major public health problem in the world. Replacing functional cardiac cells lost in 
the failing heart represents a fundamental approach in modern cardiovascular 
regenerative medicine. The advent of human induced pluripotent stem cell 
technology coupled to advances in directed cardiac differentiation protocols has 
opened new avenues for the study of human myocardial physiology and 
pathophysiology. The capacity of hPSCs to differentiate in vitro and to recapitulate 
normal cellular behavior provides an attractive model system for studying cellular 
physiology and function. hPSC-CMs hold great promise for a broad range of 
biomedical applications including cellular transplantation, cardiac signaling 
transduction studies, and in vitro disease modeling. However, compared to adult 
CMs, hPSC-CMs differentiated in vitro are relatively immature, resembling 
characteristics of embryonic CMs. These cells lack well defined cellular edges and 
mature sarcomeres, which makes it difficult to perform comprehensive profiling of 
CM functions using traditional edge detection technologies. In addition, similar to 
the fetal heart, hPSC-CMs cultured in traditional glucose rich media primarily utilize 
glycolytic pathway for energy production, unlike adult CMs which generate majority 
of their ATP from fatty acid β-oxidative. Therefore, enhancing cellular maturation 
of hPSC-CMs to appropriately represent adult human myocardial physiology in 
vitro is of great interest. 




quantitatively assess contraction kinetics, force generation and electrical activities 
concurrently at the single cell resolution. Using this methodology, we demonstrated 
the ability to uncouple CM’s biomechanical and bioelectrical responses to 
pharmacological compounds. This technology can be potentially adopted for the 
development of high throughput drug discovery and toxicity screening platforms in 
vitro. We have applied this methodology in several collaborative and published 
studies for quantitative analysis of cardiomyocyte function: Jung et al. developed 
a statistical model for enhanced murine cardiomyocyte differentiation using 3D 
extracellular matrices148. Correia et al. investigated how distinct carbon sources 
affect the structural and functional maturation of hPSC-CMs105. Tucker et al. 
characterized the impact of a novel mutation on filamin c gene on contractile 
function of cardiomyocyte derived from patient iPSCs149. This methodology also 
allowed us to quantitatively assess the functional maturation of hPSC-CMs utilizing 
different carbon sources and their responses to ischemic stresses.  
We then investigated the immature metabolic phenotype of hPSC-CM, 
which is a major limitation for its application in in vivo transplantation and clinical 
studies. We first confirmed the previous findings that hPSC-CMs cultured in 
traditional culture media rich in glucose exhibit embryonic metabolic characteristics 
utilizing primarily glycolytic pathway for energy production. Interesting, when 
supplied with both glucose and fatty acids similar to the nutrients available in the 
heart in vivo, unlike the adult heart, hPSC-CMs choose glycolysis instead of 




metabolism from glycolysis to OXPHOS. However, this treatment is not 
physiological and induced lipotoxicity after 10 days of culture as shown in previous 
study105. Consequently, we examined the underlying molecule signaling pathway 
controlling hPSC-CMs’ metabolism. We show that under standard culture 
conditions, the HIF1α-LDHA axis is aberrantly upregulated in hPSC-CMs, 
preventing their metabolic maturation. Chemical inhibition of this pathway resulted 
in an appropriate metabolic shift from aerobic glycolysis to OXPHOS. This in turn 
resulted in improved mitochondria content, sarcomere lengths, calcium handling 
and contractile functions in hPSC-CMs. These findings provide a valid strategy for 
correcting hPSC-CMs’ glycolytic phenotype and enhancing functional maturation 
to better represent the metabolism and physiology of the native adult heart in vitro.  
The next steps should be to combine different CM maturation strategies 
with chemical inhibition of HIF1α-LDHA to further mature hPSC-CMs in vitro. 
Several easily implementable approaches proven to improve CM maturation 
include gradually electrical stimulation, mechanical loading and developing tissue 
engineered constructs, all of which can be combined with our strategy. One 
strategy that should be tested, for example, is culturing hPSC-CMs with GFAM 
media in tissue engineered constructs such as Biowire with electrical pacing while 
chronically inhibit HIF1α/LDHA. By mimicking both biophysical and biochemical 
stimulations in the heart during in vivo development, this strategy has the potential 
to achieve an additive or even synergistic effect in enhancing multiple aspects of 




ultimate goal for these studies will be to induce complete maturation equivalent to 
adult cardiomyocytes that are capable of in vitro drug discovery studies and in vivo 
transplantation therapies. As shown by the results from this study, metabolic 
pathway selection plays an important role in regulating CM sarcomere lengths, 
mitochondria number, electrical and functional maturation. Thurs, it is critical to 
comprehensively assess the maturation state of hPSC-CMs when compared to 
adult CMs. It is important to note that inhibiting HIF1α using small molecule or 
siRNA may not be the most ideal strategy when using matured hPSC-CMs for in 
vitro studies such as hypoxia and IR injuries. Since HIF1α is the central regulator 
for cellular hypoxic responses, completely shutting down HIF1α pathways 
obstructs one’s ability to study CM’s hypoxic responses and model ischemic 
diseases in vitro. More physiological approaches to inhibit HIF1α for CM 
maturation should be investigated to allow for normal HIF1α activation during 
hypoxic stimulus.  
Next, we aimed to develop a physiologically appropriate model of ischemia 
reperfusion injury in vitro using hPSC-CMs. Since energy substrate availability can 
significantly impact CM physiology and function, we examined the dependency of 
glucose cultures on hPSC-CMs’ responses to ischemic injuries in vitro. hPSC-CMs 
showed reduced cellular ATP and contractility in response to hypoxic treatments 
only when cultured in media without glucose. Similar results were observed with 
chemical hypoxia using oligomycin. We then showed that coverslip IR induced 




glucose, mimicking in vivo myocardial responses to MI. These findings highlighted 
the importance of controlling cell culture environment such as limiting nutrient and 
oxygen supplies in modeling complex diseases such as IR injuries in vitro. 
Future research should focus on isolating the factors responsible for 
inducing CM death and apoptosis in the IR model. Candidates including rapid 
decreases and renormalization of pH, generation of reactive oxygen species, and 
accumulation of extracellular lactate have been proposed to induce CM damage 
and death in various studies. From the results in this study and others in the 
literature, it is likely that a combination of factors is responsible for CM death and 
apoptosis. One major advantage to model complex diseases in vitro is the ability 
to isolate specific components and interrogate its role in causing cellular phenotype. 
One area that further research can focus on is isolating the physiological changes 
during the reperfusion phase of IR injury. The beginning of the reperfusion phase 
is an attractive therapeutic window for interventions to reduce cell damage and 
deaths. Once the direct cause of IR injury has been discovered, one can perform 
in vitro screening of known or novel cardioprotective reagents targeting the precise 
mechanism of cellular apoptosis to improve CM survival after reperfusion. By using 
more physiologically appropriate conditions and cells to study CM responses in 
vitro, one can hope to better understand pathophysiology of certain diseases and 
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